

## Index of subjects Volume 9 (1998)

**A**

**ABMT**  
in patients with Hodgkin's disease 289

**9-AC**  
in advanced non-small-cell lung cancer 1085

**aclarubicin**  
for the treatment of acute myeloid leukemia (Short report) 221

**acute myeloid leukemia**  
autologous peripheral blood progenitor 151

**AVA** for the treatment in elderly patients (Short report) 221

expression of *bcl-2* mRNA as a determinant of prognosis 159

resistance to chemotherapy (Editorial) 129

**adaptation**  
of advanced stage Hodgkin's disease and acute leukemia survivors 297

**adjustment**  
psychosocial adaptation of Hodgkin's disease 297

**adjuvant**  
chemotherapy added to radiotherapy or tamoxifen (Commentary) 489

G-CSF (filgrastim)-supported FEC polychemotherapy in breast cancer patients 403

paclitaxel used for the treatment of breast cancer (Commentary) 973

**advanced**  
breast cancer  
randomised trial using letrozole and aminoglutethimide 639

colorectal carcinoma treated with  
oxaliplatin (Short report) 105

leucovorin and fluorouracil 727

leucovorin, 5-fluorouracil and oxaliplatin (Short report) 1251

head and neck cancer  
phase II trial of cisplatin and gemcitabine (Short report) 1347

stages in the treatment of Hodgkin's disease 195

aggressive lymphomas  
alternating triple therapy for the treatment of 511

conditioning regimens before transplantation (Review) SI: 15

aggressive non-Hodgkin's lymphoma  
high-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy (Review) SI: 5

**AIDS**  
treatment of a related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF (Short report) 1135

alcohol-related pain  
as a rare syndrome in Hodgkin's disease S5: 109

allograft  
in adult lymphoblastic lymphoma 619

alpha-fetoprotein  
and clinical use (Clinical case) 667

and its hereditary persistence (Clinical case) 667

alternating combination  
of irinotecan with bolus 5-fluorouracil and leucovorin in first-line chemotherapy for metastatic colorectal cancer 1199

alternating triple therapy (ATT)  
for the treatment of intermediate grade and immunoblastic lymphoma 511

amifostine  
in concurrent radiotherapy for head and neck cancer 505

**AML**, see: acute myeloid leukemia

**anecdotes**  
in evidence-based health care (Review on evidence-based cancer medicine) 963

**anemia**  
as a rare syndrome in Hodgkin's disease S5: 109

frequency and significance in non-Hodgkin's lymphoma patients 1109

induced by chemotherapy as a side effect and its treatment with rhEPO 255

**anthracycline**  
cardiotoxicity (Editorial) 691

cardiotoxicity in AIDS Kaposi's sarcoma patients 711

used in breast cancer patients (Letter to the editor) 461

used in elderly patients with non-Hodgkin's lymphoma 1219

**anthroposophical medicine**  
as an addition to the assessment of quality of life for patients with advanced cancer 1091

**antibiotic-associated diarrhea**  
in hospitalized oncology patients 307

**antiemetics**  
results of the Perugia Consensus Conference (Special article) 811

treatment for cancer chemotherapy-induced nausea and vomiting 759

**antiphospholipid syndrome**  
development of CD4 lymphocyte deficiency and non-Hodgkin's lymphoma (Letter to the editor) 921

**antiretroviral therapy**  
in HIV-related Kaposi's sarcoma (Letter to the editor) 923

**antitumor activity**  
in a melanoma model in mice 63

**apoptosis**  
its role in the molecular genetics of cancer (Commentary) 23

**aromatase inhibitors**  
for the treatment of postmenopausal women with advanced breast cancer 639

**arrhythmia**  
and torsade de pointe in relation to the dose limiting toxicities of S9788 1233

**arterial embolism**  
causing a primary osteosarcoma of the heart (Clinical case) 775

**asbestos**  
and its relation to malignant mesothelioma (Review) 139

**ascites**  
with respect to predominantly intraperitoneal malignancies 437

**autograft**  
on patients with adult lymphoblastic lymphoma 619

**autologous**  
hematopoietic stem-cell transplantation  
for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (Short report) 1023

**stem cell transplantation**  
for aggressive non-Hodgkin's lymphoma (Review) SI: 5, (Review) SI: 15

transplant

- for diffuse large-cell lymphoma in first remission (Review) SI: 9
- for diffuse large-cell non-Hodgkin's lymphoma (Review) SI: 1
- in bone marrow 289
- in primary refractory Hodgkin's disease S5: 97
- mobilized with high-dose cytarabine in AML 151
- of patients with transformed follicular lymphoma 865

**B**

Barrett's oesophagus

- cancer treatment (Review) 951

BCH-4556

- against human tumor colony-forming units 885

*bcl-2*

- high expression mRNA in acute myeloid leukemia 159
- related to the treatment of Hodgkin's lymphomas S5: 125

B-cell

- classification of lymphomas S5: 25, 45
- lymphomas and autologous transplantation 51
- non-Hodgkin's lymphoma related to clinico-pathological characterization of HCV 495

B-DLCL

- rearrangements of *bcl-6*, *bcl-2*, *c-myc* and 6q deletion 55

bias

- in evidence-based health care (Review on evidence-based cancer medicine) 963

biliary tract cancer

- treatment with 5-fluorouracil continuous infusion with cisplatin 653

biochemical modulation

- in the chemotherapy treatment of advanced colorectal cancer 727

bleomycin

- as a treatment for patients with head and neck cancer (Short report) 225

blood cell transplant

- in diffuse large-cell lymphoma (Review) SI: 23

bone marrow

- aspirate of patients with small-cell lung cancer 181
- hematopoiesis induced by interleukin-12 63
- involvement by tumor cells in patients with small-cell lung cancer (Review) 247
- transplantation in patients with Hodgkin's disease 289

bone metastasis

- of the jaw (Clinical case) 559

bone scan

- as staging procedure in breast cancer patients (Arena) 1173

bone scintigraphy

- of a osteosarcoma patient with late peritoneal metastasis (Clinical case) 907

bowel lymphoma

- in a patient with intestinal lymphangiectasia and viral warts (Letter to the editor) 1355

brachytherapy

- and external beam irradiation for localized prostate cancer 751

brain

- edema
- human corticotropin-releasing factor 71

neoplasms

- treatment of malignant glioma with chemotherapy (Review) 589

**BRCA1**

- germline mutations linked to hereditary breast and ovarian cancer (Special article) 939

**BRCA2**

- germline mutations linked to hereditary breast and ovarian cancer (Special article) 939

breast cancer

- abdominal pain with anorexia (Clinical case) 1243
- activity of multidrug resistance gene product 85
- assessment of response in primary chemotherapy (Letter to the editor) 1140
- CD44v6 expression as a prognostic factor (Short report) 109
- clinical course of patients with metastases confined to the lungs 413
- CMF chemotherapy added to radiotherapy or tamoxifen (Commentary) 489
- detection by <sup>111</sup>In-pentetetotide scan (Clinical case) 213
- dose-intensity of anthracyclines (Letter to the editor) 461
- growth stimulation in the presence of tamoxifen 205
- hematopoietic progenitor cell collection and neoplastic cell contamination in patients receiving G-CSF and chemotherapy (Short report) 913
- levels of haematological toxicity 403
- minimal residual disease in autologous hematopoietic harvests (Review) 821
- neoadjuvant chemoendocrine therapy 1179
- new treatments in patient care (Commentary) 973
- occurrence of *Pneumocystis carinii* pneumonia (Letter to the editor) 573
- paclitaxel combined with 5-fluorouracil and leucovorin as treatment 45
- primary chemotherapy as therapeutic option for patients with breast cancer (Editorial) 1151
- quality of life assessment in patients receiving adjuvant therapy (Letter to the editor) 231
- recommendations for medical management (Special article) 939
- staging procedures in clinical or research settings (Arena) 1173
- the changing landscape of clinical research (Special article) 133

breast neoplasm

- in patients with postmastectomy lymphedema 187

Burkitt's lymphoma

- in a patient with Denys-Drash syndrome 627
- related to the Epstein-Barr virus S5: 5

**C**

**C2B8**

- used in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995

calcitonin

- plasma measurements in medullary thyroid carcinoma (Review) 695

cancer

- and the development of an isolated chylopericardium (Clinical case) 1339
- and overdiagnosis by screening (Debate) 1297
- care
- the impact of specialization on the processes and outcomes (Review) 365
- cost-effectiveness analysis (Review) 475

**pain**

- equianalgesic dose/ratio between methadone and other opioid agonists 79
- somatostatin in association with morphine in advanced cancer patients (Letter to the editor)** 921
- recent advances in the molecular genetics (Commentary) 23
- registry of patients with small-cell lung cancer 543
- research (Special article) 251
- risk management without adequate data (Editorial) 929
- survivors and psychosocial adaptation of advanced stage Hodgkin's disease 297
- vaccine of hr-EGF linked to a carrier protein 431

**carboplatin**

- compared to cisplatin in solid tumors (Review) 13
- efficacy and safety in combination with paclitaxel in patients with ovarian carcinoma 37
- toxic effects on the peripheral nervous system of the rat 443

**carcinoma *in situ***

- of the testis and the effect of chemotherapy 657

**cardiac osteosarcoma**

- as a cause of recurrent peripheral arterial emboli (Clinical case) 775

**cardiotoxicity**

- in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin 711
- of anthracycline (Editorial) 691

**case-control study**

- of surviving prostate cancer patients 751

**CD20 monoclonal antibody**

- in relapsed B-cell lymphoma 527

**CD34+ HPC's**

- for autologous transplantation in B-cell non-Hodgkin's lymphomas 51

**CD4 lymphocyte deficiency**

- and non-Hodgkin's lymphoma in the antiphospholipid syndrome (Letter to the editor) 921

**CD44v6**

- as prognostic factor in primary breast cancer (Short report) 109

**cell lines**

- comparison of toxicity of different schedules of ET-743 989

**central nervous system disease**

- using prophylaxis in patients with aggressive non-Hodgkin's lymphoma 191

**central venous catheters**

- for long-term chemotherapy 767

**certification**

- and training for medical oncology through the ESMO programme (Special article) 585

**cervical cancer**

- neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel 977
- with a rib metastasis in an adult (Clinical case) 1015

**cervix carcinoma**

- the role of chemotherapy treatment (Editorial) 933

**CFU-GM**

- in cytotoxic drug therapy (Special article) 357

**chemokine**

- in immune escape mechanisms in Hodgkin's disease S5: 21

**chemoradiotherapy**

- for head and neck cancer (Editorial) 471

**chemotherapy**

- and bone marrow transplantation in adult lymphoblastic lymphoma 619
- and radiotherapy-induced emesis 811
- and r-hu-G-CSF as treatment for AIDS-related non-Hodgkin's lymphoma (Short report) 1135
- and surgery for osteosarcoma of the limbs 893
- central venous access ports for long-term treatment 767
- in early stage Hodgkin's disease S5: 57, 63
- on patients with

  - acute myeloid leukemia (Editorial) 129
  - adult lymphoblastic lymphoma 619
  - advanced biliary tract carcinoma 653
  - advanced carcinoma of the cervix (Editorial) 933
  - advanced Hodgkin's disease S5: 67, 73
  - advanced non-small-cell lung cancer (Short report) 677
  - breast cancer (Letter to the editor) 1140
  - carcinoma *in situ* of the testis 657
  - chronic lymphocytic leukemia (Editorial) 131
  - colorectal cancer liver metastasis (Arena) 967
  - HBV (Letter to the editor) 117
  - high-grade non-Hodgkin's lymphoma 1213
  - high-risk breast cancer patients 403
  - Hodgkin's disease 289, S5: 57, 63, 103
  - large cell B-cell non-Hodgkin's lymphoma (Rapid publication) 385
  - malignant glioma (Review) 589
  - malignant mesothelioma 269
  - malignant pleural mesothelioma (Review) 139
  - metastases confined to the lungs 413
  - non-small-cell lung cancer (Short report) 331, (Short report) 457, 1079
  - ovarian carcinoma 37
  - post-transplant lymphoproliferative disease (Letter to the editor) 339
  - primary breast cancer 1179
  - primary cervical malignant teratoma with a rib metastasis (Clinical case) 1015
  - primary extranodal lymphomas of the ocular adnexa (Short report) 779
  - primary mediastinal large B-cell lymphoma with sclerosis (Short report) 1027
  - testicular teratoma (Letter to the editor) 118

**chemotherapy-induced**

  - anemia associated with solid tumors 255
  - emesis antiemetic prophylactically treated 759
  - peripheral neuropathy 739

**chemotherapy-radiotherapy combination S5: 57**

**chest radiography**

  - as staging procedure for breast cancer patients (Arena) 1173

**chimeric IDEC-C2B8**

  - in relapsed B-cell lymphoma 527

**2-chlorodeoxyadenosine**

  - inducing toxicity in pretreated lymphocytic leukaemia 721

**CHOP**

  - and the treatment for intermediate grade lymphomas 511
  - in untreated patients with high-grade non-Hodgkin's lymphoma 1213

**CHOP-Mtx vs. CAPOMEt**

- in the treatment of aggressive non-Hodgkin's lymphoma 633
- chronic**
  - lymphocytic leukemia 167
    - high incidence of relapse after autologous stem-cell transplantation (Short report) 1023
    - treatment with cladribine 721
  - myeloid leukemia (Editorial) 351, 389
- chylopericardium**
  - of neoplastic aetiology (Clinical case) 1339
- cisplatin**
  - chemistry followed by granisetron plus dexamethasone in controlling delayed nausea and vomiting 661
  - chemistry followed by surgery for osteosarcoma of the limbs 893
  - combined with docetaxel as a first-line treatment of advanced non-small-cell lung cancer (Short report) 331
  - combined with gemcitabine in advanced squamous-cell carcinoma of the head and neck (Short report) 1347
  - combined with paclitaxel in patients with recurrent squamous cell carcinoma of the head and neck (Short report) 335
  - compared to carboplatin in solid tumors (Review) 13
  - resistant cell lines in ovarian cancer 423
- cladribine**
  - inducing toxicity in pretreated chronic lymphocytic leukaemia 721
- classification**
  - of lymphoma entities (Commentary) 607, S5; 45
  - of Sézary syndrome 857
- Clinical cases**
  - alpha-fetoprotein**
    - and clinical use 667
    - and its hereditary persistence 667
  - arterial embolism**
    - causing a primary osteosarcoma of the heart 775
  - bone metastasis**
    - of the jaw 559
  - bone scintigraphy**
    - of a osteosarcoma patient with late peritoneal metastasis 907
  - breast cancer**
    - abdominal pain with anorexia 1243
    - detection by  $^{111}\text{In}$ -pentetetotide scan 213
  - cancer**
    - and the development of an isolated chylopericardium 1339
  - cardiac osteosarcoma**
    - as a cause of recurrent peripheral arterial emboli 775
  - cervical cancer**
    - with a rib metastasis in an adult 1015
  - chemotherapy**
    - on patients with
      - primary cervical malignant teratoma with a rib metastasis 1015
  - chylopericardium**
    - of neoplastic aetiology 1339
  - CT scan**
    - documenting thymic and mediastinal lymph node enlargements 95
  - diagnosis**
    - of patients with unknown primary carcinoma 213
  - fever of unknown origin (FUO)**
    - caused by psoriasisform lesions as paraneoplastic manifestation in Hodgkin's disease 449
  - follow-up**
    - of patients with osteosarcoma 907
  - galliumscintigraphy**
    - for diagnosis of thymic hyperplasia 95
  - gastrointestinal metastases**
    - after malignant melanoma in breast cancer patients 1243
  - germ cell**
    - tumors**
      - and sarcoidosis 321
      - in analogy to the prognosis of malignant teratoma 1015
  - hematotoxicity**
    - of tamoxifen in patients with a liver disease 1123
  - hereditary persistence**
    - of alpha-fetoprotein 667
  - Hodgkin's disease**
    - psoriasisform lesions as paraneoplastic manifestation 449
    - invasive lobular carcinoma**
      - as predominant histological subtype of gastrointestinal metastases of breast cancer 1243
    - lymphoma**
      - primary therapy for 95
    - mandible**
      - pain as the leading clinical symptom for metastatic disease 559
    - metastatic breast cancer**
      - detection by  $^{111}\text{In}$ -pentetetotide scan 213
    - monitoring**
      - hepatic dysfunction in liver disease by tamoxifen 1123
    - neoplasia**
      - and the treatment of chylopericardium 1339
    - nodular sclerosis**
      - as a manifestation in Hodgkin's disease 449
    - nuclear medicine**
      - for primary breast cancer presenting as metastatic carcinoma of unknown primary origin 213
    - numb lip syndrome**
      - as a sign for metastatic disease (Clinical disease) 559
    - osteosarcoma**
      - late peritoneal metastasis in a patient 907
    - paraneoplastic lesions**
      - as paraneoplastic manifestation in Hodgkin's disease 449
    - pericardial effusion**
      - of chylous fluid in chylopericardium 1339
    - peritoneal metastasis**
      - in a patient with osteosarcoma 907
    - physiopathology**
      - of a patient with osteosarcoma having late peritoneal metastasis 907
    - prognosis**
      - in primary cervical malignant teratoma 1015
    - psoriasisform lesions**
      - in Hodgkin's disease 449
    - residual mass**
      - after primary therapy for lymphoma 95
    - sarcoidosis**
      - coincidence of seminoma 321
    - seminoma**
      - coincidence of sarcoidosis 321
    - skin lesions**
      - in Hodgkin's disease 449

- surgery
  - of patients with primary cervical malignant teratoma with a rib metastasis 1015
- tamoxifen
  - in liver disease as potential exacerbation of hepatic dysfunction 1123
- teratoma
  - with a rib metastasis in an adult 1015
- TIPS
  - treatment for patients with a liver disease 1123
- transesophageal echocardiography
  - performance in patients with symptoms of systemic arterial embolism 775
- tumor markers
  - the role of alpha-fetoprotein (AFP) 667
- clinical
  - correlations
    - of *bcl-6*, *bcl-2*, *c-myc* rearrangements and 6(q) deletions in B-DLCL 55
  - features
    - impact of hepatitis C virus 499
  - phase II study
    - of new drugs in the treatment of Hodgkin's disease S5: 103
  - guidelines
    - and documented clinical policies (Review on evidence-based cancer medicine) 1073
  - oncology
    - and PET scanning (Editorial) 353
  - research
    - of breast cancer (Special article) 133
  - significance
    - related to the quality of life in patients with Hodgkin's lymphoma S5: 137
  - trials (Special article) 251
    - for the treatment of adult Hodgkin's disease S5: 79
    - in the quality of life assessment in Hodgkin's disease S5: 147
  - clofazimine
    - in hepatocellular carcinoma (Short report) 217
  - clonality
    - of Hodgkin-Reed Sternberg specific immunoglobulin gene rearrangements 283
  - cloning assay
    - used for determining *in vitro* effects of ET-743 against primary human tumor specimens 981
    - used for evaluating antitumor activity of BCH-4556 885
  - Clostridium difficile* diarrhea
    - determination and validation of a predictive model in hospitalized oncology patients 307
  - CMF
    - chemotherapy added to radiotherapy or tamoxifen (Commentary) 489
  - CNS involvement
    - as a rare syndrome in Hodgkin's disease S5: 109
  - coagulation
    - prognostic impact of an activation in lung cancer (Letter to the editor) 1255
  - cognition
    - in the use of anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963
  - cognitive-spiritual quality of life
    - as important assessment for patients with advanced cancer 1091
  - colon adenocarcinoma
    - and the use of Irinotecan (Short report) 453
  - colorectal cancer
    - addition of low-dose leucovorin to monthly 5-fluorouracil 535
    - clinical and preclinical use of oxaliplatin (Review) 1053
    - 5-fluorouracil and mitomycin-C (Letter to the editor) 230
    - liver metastasis and local treatment (Arena) 967
    - prevention with a screening model employing sigmoidoscopy 613
    - screening (Editorial) 581
    - topotecan with granulocyte-colony stimulating factor 173
    - with special biological features 901
  - colorectal neoplasms
    - local treatment for colorectal cancer liver metastasis (Arena) 967
  - combined modality therapy in patients with
    - carcinoma of the esophagus 647
    - Hodgkin's disease in early stage S5: 63
    - Hodgkin's disease at advanced stages 195
    - pediatric Hodgkin's disease (Review) S5: 115
    - surgically staged IIIA-N2 non-small-cell lung cancer 261, 1193
  - communication
    - in clinical cancer research (Special article) 251
    - in evidence-based health care (Review on evidence-based cancer medicine) 963
  - concentration-controlled
    - randomised comparison of standard vs. prolonged infusions of etoposide phosphate in small-cell lung cancer 1205
  - concomitant chemoradiotherapy
    - for carcinoma of the esophagus 647
  - concurrent chemo- and radiation therapy
    - for head and neck cancer 505
  - conditioning regimen
    - before transplantation in patients with aggressive non-Hodgkin's lymphoma (Review) S1: 15
  - conduct
    - facilitated by improving quality of trial reports (Review on evidence-based cancer medicine) 483
  - conservative surgery
    - in stage I of ovarian carcinoma 1097
  - continuing education
    - in the field of cancer medicine (Review on evidence-based cancer medicine) 377
  - continuous infusion
    - with fluorouracil in the treatment of advanced colorectal cancer 727
  - corticotropin-releasing factor
    - in patients with peritumoral brain edema 71
  - cost analysis
    - in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
  - cost-effectiveness
    - analysis
      - in oncology (Review) 475
      - of clinical studies 389
    - approach to prevent colorectal cancer 613
    - of interferon-alpha (Editorial) 351
  - CPT-II
    - with bolus 5-fluorouracil and leucovorin in first-line chemotherapy for metastatic colorectal cancer 1199

cross cultural comparison  
 of the quality of life assessment in the treatment of early breast cancer 745

CT scan  
 documenting thymic and mediastinal lymph node enlargements (Clinical case) 95

cutaneous T-cell lymphoma  
 in Sézary syndrome 857

cytarabine  
 in acute myeloid leukemia mobilizing autologous peripheral blood progenitor cell transplantation 151

cytogenetics  
 for the detection of t(11;14)(q13;q32) in mantle cell lymphomas 519

cytosine arabinoside  
 for the treatment of acute myeloid leukemia (Short report) 221

cytotoxic T lymphocyte (CTL)  
 in the treatment of relapsed Hodgkin's disease S5: 129  
 response in control of an Epstein-Barr virus infection S5: 5

**D**

data interpretation  
 its role in evidence-based health care in relation to anecdotes (Review on evidence-based cancer medicine) 963

decision making  
 in relation to anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963

delayed emesis  
 controlled with granisetron plus dexamethasone or dexamethasone alone 661

dendritic cell  
 in the treatment of relapsed Hodgkin's disease S5: 129

Denys-Drash syndrome  
*WT1* involvement in a Burkitt's lymphoma 627

Dexa-BEAM regimen  
 in the treatment of patients with relapsed or refractory Hodgkin's disease 289

dexamethasone  
 in controlling delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy 661

diagnosis  
 of patients with unknown primary carcinoma (Clinical case) 213  
 of prostate carcinoma by screening (Debate) 1297

diaminocyclohexane  
 for the treatment of advanced colorectal cancers (Review) 1053

diarrhea in cancer patients  
 determination and validation of a predictive model 307

differential diagnosis  
 of Hodgkin's lymphoma and related diseases S5: 31

diffuse large-cell lymphoma  
 high-dose therapy in first remission (Review) S1: 9

DMP 840  
 administered by 24-hour infusion (Short report) 101

docetaxel  
 and cisplatin as first-line treatment of advanced non-small-cell lung cancer (Short report) 331  
 and onycholysis in patients (Letter to the editor) 230  
 as substitution of paclitaxel (Letter to the editor) 573

dose escalation  
 in BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67

dose intensification  
 in the treatment of adult Hodgkin's disease S5: 79

dose-intensity  
 of anthracyclines in breast cancer (Letter to the editor) 461

dose response relationship  
 in patients with Hodgkin's disease receiving BEACOPP regimen S5: 73

doxorubicin  
 in the treatment of adult patients with soft tissue sarcoma (Short report) 783, (Short report) 917  
 in the treatment of patients with a lack of activity in poor prognosis soft tissue sarcomas (Short report) 1131  
 development in clinical cancer research (Special article) 251  
 for patients with advanced non-small-cell lung cancer (Short report) 457  
 utilization for cancer chemotherapy-induced nausea and vomiting 759

drug-dependent platelet antibody  
 in the presence of Irinotecan (Short report) 453

**E**

early breast cancer  
 treatment with CMF and Zoledex (Goserelin) 745

early stages  
 of Hodgkin's disease S5: 63

EBV  
 positive Hodgkin's lymphoma S5: 45

EBV-associated lymphoproliferative disease (EBV-LPD)  
 and the treatment of relapsed Hodgkin's disease S5: 129

economic evaluation  
 in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167

ecteinascidins  
 against human tumors explanted from patients 981

in vitro schedule-dependency of myelotoxicity and cytotoxicity 989

education  
 in relation to evidence-based health care (Review on evidence-based cancer medicine) 963

effectiveness  
 of antiemetic drugs in patients undergoing cancer chemotherapy 759

efficacy  
 of BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67

elderly patients  
 with acute myeloid leukemia (Short report) 221  
 with non-Hodgkin's lymphoma 1219

emission computed tomography  
 after induction chemotherapy in non-small-cell lung cancer 1193

endomyocardial biopsy  
 to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients 711

endpoint  
 for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer 1079

EORTC QLQ-C30  
 evaluation of the questionnaire and long-survival cancer patients 549

epidemiology  
 of patients with malignant pleural mesothelioma (Review) 139

- of Hodgkin's lymphoma S5: 45
- of the non-Hodgkin's lymphomas 717
- of vulvar and vaginal cancers 1229
- epidermal growth factor
  - in relation to the antineoplastic activity of suramin in patients with breast cancer 205
  - linked to a carrier protein as a novel cancer vaccine 431
- epithelial tumor cells
  - detection in blood or bone marrow (Review) 1269
- Epstein-Barr virus
  - in Hodgkin's lymphoma S5: 5
  - in relapsed Hodgkin's disease S5: 129
- equianalgesia
  - in cancer pain treatment 79
- erythropoietin
  - in patients with solid tumours (Editorial) 239
  - in the prevention of transfusion requirement 255
  - in the treatment of chemotherapy-induced anemia 255
- ESMO-MORA
  - programme of certification and training for medical oncology (Special article) 585
- esophageal carcinoma
  - a long-term analysis of a combined modality therapy 647
- etoposide
  - addition to CHOP chemotherapy in patients with non-Hodgkin's lymphoma 1213
  - for the treatment of acute myeloid leukemia (Short report) 221
  - for the treatment of small-cell lung cancer 1205
- evidence
  - in reducing mortality from prostate cancer due to PSA screening (Debate) 1293
- evidence-based medicine (Review on evidence-based cancer medicine) 377, 703, 963
- Ewing tumor
  - Survival analysis of patients from the EICESS studies 275
- extended field radiation
  - in the treatment of Hodgkin's disease S5: 79
- extranodal lymphomas
  - treatment and prognosis in the ocular adnexa (Short report) 779
  - workshop on peripheral T-cell lymphomas (Commentary) 835
- F**
  - famciclovir
    - in the treatment of patients with high-grade non-Hodgkin's lymphoma (Rapid publication) 385
  - FAS
    - in Hodgkin's disease immune escape mechanisms S5: 21
  - FASL
    - in Hodgkin's disease immune escape mechanisms S5: 21
  - fatigue
    - and the impact on quality of life of Hodgkin's lymphoma survivors S5: 137
  - FDG-PET
    - for accurate staging of Hodgkin's disease 1117
  - feasibility study
    - of a chimeric anti-CD20 monoclonal antibody in relapsed B-cell lymphoma 527
  - fes/fps
    - oncogene related to the treatment of Hodgkin's lymphomas S5: 125
- fever of unknown origin (FUO)
  - caused by psoriasisform lesions as paraneoplastic manifestation in Hodgkin's disease (Clinical case) 449
- F-fluorodeoxyglucose (FDG)
  - PET in the detection of liver metastases 397
- first-line chemotherapy
  - of metastatic colorectal cancer 1199
- first remission
  - of Hodgkin's disease patients S5: 83
- fluorescence *in situ* hybridization
  - for the detection of the t(11;14) region in mantle cell lymphomas 519
- fluorouracil
  - used for the treatment of advanced colorectal carcinoma 535, 727
- 5-fluorouracil
  - biochemical modulation in patients with advanced colorectal cancer 1309
  - used in combination with leucovorin and oxaliplatin in the treatment of metastatic colorectal cancer (Short report) 1251
- follicular lymphoma
  - for the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995
  - histologic transformation (Editorial) 803
- follow-up
  - of patients with osteosarcoma (Clinical case) 907
- Frey's syndrome
  - after cisplatin-based chemotherapy for testicular teratoma (Letter to the editor) 118
- G**
  - G-CSF (filgrastim)
    - supported FEC polychemotherapy in high-risk breast cancer patients 403
    - used for mobilization in breast cancer patients (Short report) 913
    - with CNOP in the treatment of AIDS-related non-Hodgkin's lymphoma (Short report) 1135
  - galliumscintigraphy
    - for diagnosis of thymic hyperplasia (Clinical case) 95
  - gastrointestinal metastases
    - after malignant melanoma in breast cancer patients (Clinical case) 1243
  - gemcitabine
    - causing hemolytic-uremic syndrome (Letter to the editor) 1355
    - combined with cisplatin regimen for patients with non-small-cell lung cancer (Short report) 457
    - combined with paclitaxel in patients with refractory solid tumors 733
    - for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy (Short report) 1127
    - in patients with solid tumors 1003
    - in platinum pre-treated patients with advanced epithelial cancer 1343
    - in pretreated peripheral T-cell lymphoma patients (Short report) 1351
    - in the treatment of Hodgkin's disease S5: 103
    - inducing veno-occlusive disease of the liver (Letter to the editor) 681
  - gene-marking
    - in relapsed Hodgkin's disease patients S5: 129
  - gene therapy
    - for malignant glioma (Review) 589, (Review) 1155

- gene transfer
  - in relapsed Hodgkin's disease patients S5: 129
- genetic
  - lesions in B-diffuse large-cell lymphoma 55
  - polymorphism in a promoter region of *UGT1A1* (Rapid publication) 845
- geography
  - in the distributions of the major subtypes in the epidemiology of non-Hodgkin's lymphoma's 717
- germ cell
  - cancer
    - treatment after failed high-dose therapy (Letter to the editor) 787
  - tumors
    - and sarcoidosis (Clinical case) 321
    - in analogy to the prognosis of malignant teratoma (Clinical case) 1015
- glioma
  - treatment with chemotherapy or experimental methods (Review) 589
- glucuronidation
  - of SN-38, the active metabolite of irinotecan (Rapid publication) 845
- gonadal dysfunction after chemotherapy
  - in pediatric Hodgkin's disease (Review) S5: 115
- grading
  - severity of chemotherapy-induced peripheral neuropathy 739
- graft-versus-lymphoma
  - effects in the treatment of lymphoma (Review) S1: 31
- granisetron
  - plus dexamethasone in delaying nausea and vomiting in patients receiving emetogenic chemotherapy 661
- granulocyte colony-stimulating factor
  - in a melanoma model in mice 63
  - in fluoropyrimidine-refractory colorectal cancer 173
- grey zone
  - between classical Hodgkin's lymphoma and non-Hodgkin's lymphoma S5: 31
- grey zone lymphoma
  - treatment of (Review) S5: 121
- Groshong catheter
  - used for long-term chemotherapy 767
- growth
  - factors in ascites of ovarian cancer patients 437
  - stimulation in the presence of tamoxifen 205
- guidance
  - of service, other guidelines and documented clinical policies (Review on evidence-based cancer medicine) 1073
- guideline development
  - and documented clinical policies (Review on evidence-based cancer medicine) 1073
- gynecological sarcomas
  - treatment with combined high-dose ifosfamide and doxorubicin 877
- H**
  - hCRF**
    - in patients with peritumoral brain edema 71
  - HCV**
    - and lymphoproliferative diseases (Editorial) 469
- head and neck cancer
  - an EORTC-ECSG phase II study of vinorelbine 1103
  - paclitaxel in combination with cisplatin as a treatment (Short report) 335
  - selective cytoprotection with amifostine in concurrent radiochemotherapy 505
  - the therapeutic index of concomitant chemoradiotherapy (Editorial) 471
  - vinorelbine, bleomycin and methotrexate as a salvage therapy (Short report) 225
- health
  - economics
    - cost-effectiveness analysis (Review) 475
    - cost-effectiveness approach for the prevention of colorectal cancer 613
  - outcome assessment
    - in a cohort of Italian long-survival cancer patients 549
- health-related quality of life
  - in patients with Hodgkin's lymphoma S5: 137
  - in patients with long-survival cancer patients 549
- hematopoietic stem cell transplantation
  - in chronic lymphocytic leukemia 167
- hematotoxicity
  - of a cytotoxic drug (Special article) 357
  - of tamoxifen in patients with a liver disease (Clinical case) 1123
- hematotoxicology
  - in relation to Ecteinascidin (ET-743) 989
- hemolytic-uremic syndrome
  - caused by gemcitabine (Letter to the editor) 1355
- hepatitis
  - B virus infection following intensive therapy for high-grade non-Hodgkin's lymphoma (Rapid publication) 385
- C virus
  - impact of infection on patients with lymphoplasmacytoid lymphoma/immunocytoma 499
  - related to B-cell non-Hodgkin's lymphomas 495
  - prevention of development (Letter to the editor) 117
- hepatocellular carcinoma
  - treated with oral clofazimine (Short report) 217
- Herceptin®
  - in new treatments for breast cancer (Commentary) 973
- hereditary persistance
  - of alpha-fetoprotein (Clinical case) 667
- heterozygosity
  - loss in patients with non-small-cell lung cancer patients (Short report) 113
- high-dose
  - chemotherapy on patients with
    - aggressive non-Hodgkin's lymphoma (Review) S1: 15
    - breast cancer (Review) 821
    - Hodgkin's disease S5: 87
    - relapsed or refractory Hodgkin's disease 289
  - doxorubicin
    - in the treatment of advanced sarcomas 877
  - ifosfamide
    - for soft tissue sarcomas (Editorial) 907
  - in adult patients with advanced soft tissue sarcoma (Short report) 783
  - in advanced soft tissue sarcomas of the adult 871

- in the treatment of advanced sarcomas 877
- plus adriamycin in the treatment of adult advanced soft tissue sarcomas (Short report) 917
- therapy
  - for aggressive non-Hodgkin's lymphoma (Review) SI: 5
  - for diffuse large-cell lymphoma in first remission (Review) SI: 9
- high-grade non-Hodgkin's lymphoma
  - addition of etoposide to CHOP chemotherapy in untreated patients 1213
- histologic
  - subtypes
    - in the epidemiology of the non-Hodgkin's lymphomas 717
    - transformation in follicular lymphoma (Editorial) 803
- histological type
  - and microsatellite instability of HNPCC families 901
- histopathology
  - of lymphocyte predominance Hodgkin's disease S5: 39
- HIV-1 viral replication
  - treatment for non-Hodgkin's lymphoma (Short report) 1135
- Hodgkin's disease
  - accurate staging with FDG-PET 1117
  - appearance of thymic mass after therapy for lymphoma 95
  - BEACOPP chemotherapy as new regimen S5: 67
  - classification of lymphoma entities (Commentary) 607, S5: 25
  - clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells S5: 17
  - comparison of psychological adaptation 297
  - current clinical trials for treatment of adult patients S5: 79
  - direction of identical Hodgkin-Reed Sternberg cell specific immunoglobulin rearrangements 283
  - high-dose therapy with stem cell rescue in first remission S5: 83
  - immune escape mechanisms S5: 21
  - in relation to the Epstein-Barr virus S5: 5
  - long term toxicity of the treatment S5: 133
  - lymphocyte predominance S5: 39
  - new drugs in the treatment S5: 103
  - occurring in a child after liver transplantation (Short report) 673
  - psoriasiform lesions as paraneoplastic manifestation (Clinical case) 449
  - quality of life assessment S5: 147
  - pathology S5: 45
  - primary refractory S5: 97
  - radiation therapy as a component of high dose salvage strategies S5: 87
  - radiotherapy in early stage S5: 57, 63
  - rare syndromes S5: 109
  - role of moderate dose escalation in a randomised trial S5: 73
  - salvage therapy S5: 87
  - survivors and the quality of life S5: 137
  - treatment of grey zone lymphomas (Review) S5: 121
  - treatment of the relapse S5: 91, 129
  - treatment with
    - high-dose chemotherapy and stem cell rescue 289
    - three cycles of ABVD and high-dose extended irradiation 195
  - workshop report on 'grey zone' lymphoma S5: 31
- 5-HT<sub>3</sub> antagonists
  - in the management of cancer chemotherapy-induced nausea and vomiting 759
  - in the prevention of chemotherapy- and radiotherapy-induced emesis (Special article) 811
- 5-HT<sub>3</sub>-receptor antagonist
  - in the management of delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy 661
- hydromorphone
  - methadone as an alternative for treating cancer pain 79

**I**

- IDEc
  - in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995
- ifosfamide
  - in patients with anthracycline-resistant metastatic breast cancer (Short report) 565
  - in patients with osteosarcoma of the limbs 893
- Ig gene rearrangements
  - in Hodgkin's disease S5: 17
- IL-10
  - in Hodgkin's disease immune escape mechanisms S5: 21
  - immune thrombocytopenia
    - after treatment with Irinotecan (Short report) 453
  - immunocytochemistry
    - used in the detection of contaminating epithelial tumor cells (Review) 1269
  - immunoglobulin gene rearrangements
    - in patients with Hodgkin's disease 283
  - immunohistochemistry
    - and the distinction between Hodgkin's disease and related diseases S5: 31
    - in a case of Hodgkin's disease occurring in a child after liver transplantation (Short report) 673
  - immunology
    - of Sézary syndrome 857
  - immunomagnetic purging
    - of peripheral blood CD34+ cells 51
  - immunophenotype
    - of various Hodgkin's lymphomas S5: 45
  - immunotherapy
    - for patients with Hodgkin's disease S5: 5, 103, 129
    - for patients with malignant glioma (Review) 589
    - for patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995
    - in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma (Review) SI: 31
  - incidence
    - from prostate cancer 31
    - of second neoplasms following vaginal and vulvar cancers 1229
  - individual patient data
    - systematic reviews (Review on evidence-based cancer medicine) 827
  - individualized chemotherapy
    - in high-risk breast cancer patients 403
  - induced tumours
    - as a result of late radiation in patients with early stage Hodgkin's disease S5: 63
  - induction chemotherapy
    - for carcinoma of the esophagus 647
    - in non-small-cell lung cancer 261
  - induction failure

in primary refractory Hodgkin's disease S5: 97

infection

- as an effect of dose reduction of cladribine in pretreated chronic lymphocytic leukaemia 721

information

- retrieval in its role to solve clinical questions (Review on evidence-based cancer medicine) 377
- technology in its role to solve clinical questions (Review on evidence-based cancer medicine) 377

*in situ* hybridization

- in a case of Hodgkin's disease occurring in a child after liver transplantation (Short report) 673

insulin-like growth factor-1

- in human breast cancer cell lines after tamoxifen therapy 205

interferon

- in chronic myeloid leukemia 389

interferon-alpha

- for chronic myeloid leukemia (Editorial) 351
- in HBV carriers (Letter to the editor) 117
- in the treatment of patients with lymphoma (Review) S1: 31

interleukin-2

- in the treatment of patients with lymphoma (Review) S1: 31

interleukin-12

- in combination with GF-CSF preventing the suppression of bone marrow hematopoiesis 63

intermediate grade lymphomas

- alternating triple therapy for the treatment of 511

international cooperation

- in cancer research (Special article) 251

Internet

- its role in solving clinical questions (Review on evidence-based cancer medicine) 377

intraarterial therapy

- for osteosarcoma of the limbs 893

*in vitro* assays

- schedule-dependency of myelotoxicity of Ecteinascidin 743 (ET-743) 989

*in vitro* tests

- predicting hematological toxicity of cytotoxic drug therapy (Special article) 357

invasive lobular carcinoma

- as predominant histological subtype of gastrointestinal metastases of breast cancer (Clinical case) 1243

Irinotecan

- in first-line chemotherapy of metastatic colorectal cancer 1199
- inducing immune thrombocytopenia (Short report) 453
- metabolized by esterase to form SN-38 (Rapid publication) 845
- irradiation
- for localized prostate cancer 751

**J**

JAK

- related to the treatment of Hodgkin's lymphomas S5: 125

**K**

Kaposi's sarcoma

- highly active antiretroviral therapy (Letter to the editor) 923
- patients treated with pegylated liposomal doxorubicin 711
- keeping up-to-date

of medical literature (Review on evidence-based cancer medicine) 377

**L**

L-nucleoside analogue

- activity against human tumor colony-forming units 885
- lamivudine
- in the treatment for hepatitis B infection after therapy for non-Hodgkin's lymphoma (Rapid publication) 385

late toxicity

- after treatment of Hodgkin's disease S5: 63, 133

latent membrane protein 2 (LMP2)

- used in the treatment of patients with relapsed Hodgkin's disease S5: 129

letrozole

- and aminoglutethimide in postmenopausal women with advanced breast cancer 639

leucovorin

- in combination with 5-fluorouracil and oxaliplatin for metastatic colorectal cancer (Short report) 1251

leukemia

- classification published by the WHO S5: 25
- survivors and their psychosocial adaptation 297

life situation questionnaire (LSQ)

- for analysing the quality of life of patients with Hodgkin's disease S5: 147

limited stages

- of Hodgkin's disease S5: 57

liposomal doxorubicin

- in poor prognosis soft tissue sarcomas (Short report) 1131

liver

- cancer
- assessment of metastatic involvement 397

metastasis

- detection with whole-body <sup>18</sup>F-fluorodeoxyglucose positron emission tomography 397
- local treatment in colorectal cancer patients (Arena) 967

transplantation

- followed by Hodgkin's disease in a child (Short report) 673

ultrasonography

- as staging procedure for breast cancer patients (Arena) 1173

veno-occlusive disease induced by gemcitabine (Letter to the editor) 681

localized prostate cancer

- treated with brachytherapy and external beam irradiation 751

long QT

- interval on ECG in patients with ventricular arrhythmia and torsade de pointe 1233

long-survival cancer patients

- comparison with SF-36 Health Survey 549

low-dose

- chemotherapy in the treatment of PTLD following solid organ transplantation (Letter to the editor) 339

leucovorin added to monthly 5-fluorouracil in advanced colorectal carcinoma 535

low grade

- non-Hodgkin's lymphoma and the treatment with Rituximab 995

lung

- metastases for germ-cell tumours 1185

- metastases in breast cancer 413
- surgery on patients treated with VIP induction chemotherapy 261
- lung cancer**
  - activation of coagulation (Letter to the editor) 1255
  - and new cytotoxic agents 1079
- lymph node**
  - in patients with stage I ovarian carcinoma 1097
- lymphatic metastasis**
  - combined modality treatment for N<sub>2</sub> non-small-cell lung cancer 1193
- lymphoma**
  - chimeric anti-CD20 monoclonal antibody in 527
  - classification published by the WHO S5: 25
  - frequency and significance of anemia in patients with 1109
  - high-dose therapy for (Review) SI: 9
  - pathology of various types S5: 45
  - primary therapy for (Clinical case) 95
  - tumor vaccination in combination with autologous stem cell transplantation (Review) SI: 41
- lymphoplasmacytoid lymphoma/immunocytoma**
  - impact of HCV infection on clinical features, quality of life and survival of patients 499
- lymphocyte predominance**
  - of Hodgkin's disease S5: 39
- lysolipids**
  - in the peritoneal spread of ovarian cancer 437
- lysophosphatidic acid**
  - in malignant effusions 437

**M**

**MABTHERA**

- in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995

**malignancy**

- and rhEPO in the treatment of chemotherapy-induced anemia 255

**malignant lymphoma**

- classification (Commentary) 607

**MALIGNANT mesothelioma (Review) 139**

**MALT lymphomas**

- treatment and prognosis (Short report) 779

**mandible**

- pain as the leading clinical symptom for metastatic disease (Clinical case) 559

**mantle-cell lymphoma**

- chromosomal translocation t(11;14)(q13;q32) in 519

**marine natural products**

- against hematological and solid malignancies (Editorial) 937

**marrow transplant**

- in diffuse large-cell lymphoma (Review) SI: 23

**mass screening**

- for prostate cancer (Debate) 1279

**mastectomy**

- in neoadjuvant chemoendocrine therapy in primary breast cancer 1179

**MDR**

- modulator S9788 used in patients with ventricular arrhythmia and torsade de pointe 1233

**MDRI gene**

- in primary human breast cancer 85

**media**

- in evidence-based health care (Review on evidence-based cancer medicine) 963

**mediastinum**

- in large B-cell lymphoma with sclerosis (Short report) 1027

**medical oncology**

- certification and training through the ESMO programme (Special article) 585

**medullary thyroid carcinoma**

- current diagnosis and management (Review) 695

**melanoma**

- from an occult primary lesion 419
- model in mice 63

**MEN II**

- in patients with medullary thyroid carcinoma (Review) 695

**mesothelioma**

- good symptom relief with palliative MVP chemotherapy 269

**meta-analysis**

- in the field of economy in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
- of reviews using individual patient data (Review on evidence-based cancer medicine) 827
- of studies in clinical medicine (Review on evidence-based cancer medicine) 601, 703

**metastases**

- confined to the lungs of breast cancer patients 413

**metastatic breast cancer**

- bi-weekly paclitaxel as first-line treatment (Short report) 1247
- treatment with paclitaxel, 5-fluorouracil and leucovorin 45
- detection by <sup>111</sup>In-pentetetotide scan (Clinical case) 213
- ifosfamide in association with vinorelbine in patients with (Short report) 565

**metastatic colorectal cancer**

- a phase II study of irinotecan, 5-fluorouracil and leucovorin in first-line chemotherapy 1199

**methadone**

- compared to morphine for the treatment of cancer pain 79

**methotrexate**

- as a treatment for patients with head and neck cancer (Short report) 225

**5-methylhydrofolate**

- for biochemical modulation of fluorouracil in patients with advanced colorectal cancer 1309

**micromanipulation**

- in Hodgkin's disease S5: 17

**microsatellite shift**

- in patients with non-small-cell lung cancer (Short report) 113

**minimal disease**

- detection in blood or bone marrow 1269

**minimal residual disease**

- assessed by cytofluorometry and PCR in patients with chronic lymphocytic leukemia 167

**in autologous hematopoietic harvests from breast cancer patients (Review) 821**

- in the immunotherapy for lymphoma (Review) SI: 31

**minor groove binding agents**

- against human tumors explanted from patients 981

**mixed cryoglobulinemia type II**

- pathogenesis of and associated with lymphoplasmacytoid lymphoma 495

- mobilization
  - of G-CSF and CTX in breast cancer patients (Short report) 913
- molecular
  - biology of breast cancer (Special article) 133
  - genetics of cancer and its recent advances (Commentary) 23
  - genetics of Hodgkin's lymphoma S5: 45
  - remissions in patients with chronic lymphocytic leukemia 167
- monoclonal antibodies
  - for treatment of patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995
  - in relapsed B-cell lymphoma 527
  - prognostic value of bone marrow involvement in small-cell lung cancer (Review) 247
  - staining of bone marrow aspirates in patients with small-cell lung cancer 181
- monitoring
  - hepatic dysfunction in liver disease by tamoxifen (Clinical case) 1123
- morphine
  - in association with somatostatin in advanced cancer patients with pain (Letter to the editor) 921
- mortality
  - from prostate cancer in Vaud and Neuchâtel, Switzerland 31
  - from prostate cancer reduced by PSA screening (Debate) 1293
- multidrug resistance
  - and P-glycoprotein expression in human neuroblastoma cells 1009
  - gene product in primary human breast cancer 85
- multimodality treatment
  - of oesophageal cancer (Review) 951
- multiple tumours
  - descriptive epidemiology of vulvar and vaginal cancers 1229
- multistep progression
  - in tumour types (Commentary) 23
- multivariate analysis
  - of clinical, haematological and immunological features 857
- mycosis fungoïdes
  - in patients with peripheral T-cell lymphoma (Short report) 1251
- myelosuppression
  - of cytotoxic drug therapy (Special article) 357
- myelotoxicity
  - in pretreated chronic lymphocytic leukaemia 721
- N**
  - N2-disease
    - VSP as a suitable regimen 261
  - nail disorders
    - induced by dose-intensified paclitaxel (Letter to the editor) 1139
  - narrative reviews
    - in clinical medicine (Review on evidence-based cancer medicine) 601
  - nasopharyngeal cancer
    - activity of paclitaxel by infusion in Asian patients (Short report) 327
  - neoadjuvant chemotherapy
    - for locally advanced squamous-cell cervical cancer 977
    - in primary breast cancer 1179
  - neoplasia
    - and the treatment of chylopericardium (Clinical case) 1339
  - neoplasms
    - descriptive epidemiology in vaginal and vulvar cancers 1229
- O**
  - occult
    - primary lesion of patients with visceral metastatic melanoma 419
    - ocular adnexal lymphomas
      - treatment and prognosis (Short report) 779
  - OEPA
    - used for the treatment of pediatric Hodgkin's disease (Review) S5: 115
  - oesophageal cancer
    - treatment with multimodality therapy (Review) 951

oncology  
 cost-effectiveness analysis (Review) 475

onycholysis  
 in patients treated with docetaxel (Letter to the editor) 230

opioid agonists  
 in cancer pain 79

OPPA  
 used for the treatment of pediatric Hodgkin's disease (Review) S5: 115

oral  
 antiemetic  
 the role of granisetron and dexamethasone in patients receiving highly emetogenic chemotherapy 661

chemotherapy  
 in a phase I clinical and pharmacokinetic study 1315

platinum analogue  
 in a phase I clinical and pharmacokinetic study 1315

osteosarcoma  
 intensive multidrug chemotherapy and surgery 893  
 late peritoneal metastasis in a patient (Clinical case) 907

outcome  
 assessment with PET after IC in N<sub>2</sub> non-small-cell lung cancer 1193

impact on clinical 55

of care for cancer patients (Review) 365

of questions regarding PSA screening (Debate) 1283

ovarian cancer  
 accuracy of staging as an important prognostic determinant in stage I 1097

consolidation therapy (Letter to the editor) 229

DNA-topoisomerase I activity and content 313

efficacy and safety of the paclitaxel and carboplatin combination 37

LPA-like activity in the peritoneal spread 437

multiple changes in cisplatin-resistant cell lines 423

oxaliplatin in the treatment (Review) 1053

recommendations for medical management (Special article) 939

study of gemcitabine in platinum pre-treated patients (Short report) 1343

overdiagnosis  
 of prostate carcinoma by screening (Debate) 1297

oxaliplatin  
 in colorectal carcinoma patients (Short report) 105

in combination with high-dose leucovorin and 5-fluorouracil (Short report) 1251

in the treatment of advanced colorectal cancers (Review) 1053

in the treatment of metastatic colorectal cancer (Short report) 1251

**P**

P-glycoprotein  
 activity in primary human breast cancer 85  
 expression in human neuroblastoma cells 1009  
 toxicity of S9788 in blocking concentrations for patients with ventricular arrhythmia and torsade de pointe 1233

paclitaxel  
 activity in Asian patients with nasopharyngeal cancer (Short report) 327

clinical phase I study with one-hour infusion (Short report) 569

combined with cisplatin and ifosfamide in locally advanced squamous-cell cervical cancer 977

combined with 5-fluorouracil plus leucovorin in the treatment of metastatic breast cancer 45

combined with gemcitabine for patients with non-small-cell lung cancer (Short report) 1127

combined with gemcitabine in patients with refractory solid tumors 733

combined with ifosfamide and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer (Short report) 677

hypersensitivity reactions (Letter to the editor) 573

in a first-line treatment in metastatic breast cancer (Short report) 1247

inducing multiple nail disorders (Letter to the editor) 1139

pain  
 methadone and other agonists for the treatment of cancer patients 79

palliative medicine and supportive care  
 as assessment of quality of life 1091

paraneoplastic lesions  
 as paraneoplastic manifestation in Hodgkin's disease (Clinical case) 449

pathology  
 and carboplatin toxic effects 443

in cases of Hodgkin's disease and related diseases S5: 31, 45

patterns of care  
 in a population-based study on survival of small-cell lung cancer patients 543

PBSCT  
 as a predictor of toxicity for patients with Hodgkin's disease 289

PCR  
 the detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements 283

pegylated liposomal doxorubicin  
 for patients with Kaposi's sarcoma 711

pericardial effusion  
 of chylous fluid in chylopericardium (Clinical case) 1339

peripheral  
 blood stem cell transplantation  
 for patients with diffuse large-cell lymphoma (Review) SI: 9

neurotoxicity  
 evaluation and interpretation of the studies using different scales 739

T-cell lymphoma  
 as a developing concept (Editorial) 797  
 initial features, natural history and prognostic factors 849  
 report of the European Task Force (Commentary) 835  
 therapy with gemcitabine (Short report) 1351

peritoneal metastasis  
 in a patient with osteosarcoma (Clinical case) 907

PET scanning  
 in clinical oncology (Editorial) 353  
 in the detection of liver metastases 397  
 showing bilaterally mediastinal uptake in relation to seminoma and sarcoidosis (Letter to the editor) 924

pharmacodynamics  
 in a phase I and pharmacologic study of DMP 840 (Short report) 101

pharmacoeconomics  
 cost-effectiveness in oncology (Review) 475

- cost-effectiveness of interferon in chronic myeloid leukemia 389
- pharmacokinetics
  - analysis of DMMP 840 (Short report) 101
  - for fluoropyrimidine-refractory colorectal cancer 173
  - of SN-38 and its glucuronide, depending on the genotypes of UGT1A1 (Rapid publication) 845
  - study of anti-CD20 monoclonal antibody in relapsed B-cell lymphoma 527
- phase I
  - clinical and pharmacokinetic study of the oral platinum analogue JM216 1315
  - clinical trial
    - of *in vitro* tests predicting myelosuppression of cytotoxic drug (Special article) 357
    - of paclitaxel and gemcitabine in patients with refractory solid tumors 733
    - study
      - of DMP 840 administered by 24-hour infusion (Short report) 101
      - with one-hour paclitaxel infusion (Short report) 569
    - trial
      - of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors 1003
      - of novel anti-cancer agents (Special article) 1047
- phase II
  - study of
    - a novel gemcitabine plus cisplatin regimen for non-small-cell lung cancer (Short report) 457
    - bimonthly leucovorin, 5-fluorouracil and oxaliplatin for metastatic colorectal cancer (Short report) 1251
    - gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer (Short report) 1343
    - treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin (Short report) 331
    - high-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer 173
    - oral clofazimine in unresectable and metastatic hepatocellular carcinoma (Short report) 217
    - oxaliplatin in previously untreated colorectal carcinoma patients (Short report) 105
    - paclitaxel in combination with cisplatin in squamous cell carcinoma of head and neck (Short report) 335
    - vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 1103
  - trials
    - of cisplatin and gemcitabine in advanced squamous-cell carcinoma of head and neck (Short report) 1347
    - of Doxil (liposomal doxorubicin) (Short report) 1131
    - of non-small-cell lung cancer treated with paclitaxel and gemcitabine (Short report) 1127
    - in lung cancer (Editorial) 1045, 1079
    - of novel anti-cancer agents (Special article) 1047
- phase III
  - study of the
    - impact of adding leucovorin to 5-fluorouracil in advanced colorectal carcinoma 535
    - role of pneumatic compression in the treatment of postmastectomy lymphedema 187
  - trial
- comparing low-dose leucovorin and fluorouracil with high-dose fluorouracil for colorectal cancer 727
- pheochromocytoma
  - in patients undergoing thyroidectomy for medullary thyroid carcinoma (Review) 695
- photodynamic therapy
  - of malignant pleural mesothelioma (Review) 139
- physiopathology
  - of a patient with osteosarcoma having late peritoneal metastasis (Clinical case) 907
- platinum
  - in the treatment of advanced colorectal cancers (Review) 1053
- pneumatic compression
  - in the treatment of postmastectomy lymphedema 187
- pneumocystis carinii*
  - pneumonia in breast cancer (Letter to the editor) 573
- population-based registry
  - of elderly patients with non-Hodgkin's lymphoma in the Netherlands 1219
- ports
  - connected to a Groshong catheter used for long-term chemotherapy 767
- positive immunostaining
  - in patients with small-cell lung cancer 181
- post-transplant lympho-proliferative disorder/disease
  - in a child developing Hodgkin's disease (Short report) 673
  - linked to the Epstein-Barr virus S5: 5
- prediction model
  - of hematological toxicity of cytotoxic drug (Special article) 357
- preferences
  - of using anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963
- prevention
  - for patients with an observed reduction in breast cancer (Commentary) 973
- preventive care
  - for patients with hereditary breast and ovarian cancer (Special article) 939
- primary
  - breast cancer
    - prognostics of CD44v6 (Short report) 109
    - chemotherapy
      - as a better therapeutic option for patients with breast cancer (Editorial) 1151
    - metastases
      - in Ewing tumor 275
    - refractory
      - Hodgkin's disease S5: 97
  - progenitor cells
    - transplantation in acute myeloid leukemia in first complete remission 151
  - prognosis in
    - acute myeloid leukemia 159
    - blood or bone marrow tumor cells (Review) 1269
    - lymphocyte predominance Hodgkin's disease S5: 39
    - peripheral T-cell lymphomas 849
    - primary cervical malignant teratoma (Clinical case) 1015
    - Sézary syndrome 857
    - small-cell lung cancer (Review) 247

stage I ovarian carcinoma 1097  
 visceral metastatic melanoma 419

**prognostic factor**  
 for salvage in Hodgkin's disease S5: 9  
 in diffuse large-cell lymphoma in first remission (Review) S1: 9  
 in intermediate grade and immunoblastic lymphoma 511  
 in primary breast cancer (Short report) 109  
 in Sézary syndrome 857  
 in non-Hodgkin's lymphoma patients with anemia 1109

**prognostic impact**  
 of an activation of coagulation in lung cancer (Letter to the editor) 1255

**prolonged infusion**  
 in patients with solid tumors 1003

**prophylactic treatment**  
 of patients with aggressive non-Hodgkin's lymphoma 191

**prostate**  
 overdiagnosis of carcinoma by screening (Debate) 1297

**prostate cancer**  
 and the controversy of PSA screening (Debate) 1283, (Debate) 1293  
 incidence, mortality and survival in Vaud, Switzerland 31  
 screening or watchful waiting (Editorial) 9  
 screening with prostate specific antigen (PSA) 1263

**prostate specific antigen**  
 screening for prostate cancer (Debate) 1279  
 testing as screening for prostate cancer (Editorial) 1263

**prostatic neoplasia**  
 the use of PSA screening (Debate) 1279

**protein kinase C**  
 related to the treatment of Hodgkin's lymphomas S5: 125

**protein density**  
 of the amount of peritumoral edema in the brain 71

**pruritus**  
 as a rare syndrome in Hodgkin's disease S5: 109

**PSA**  
 screening for prostate cancer (Debate) 1293

**psoriasisiform lesions**  
 in Hodgkin's disease (Clinical case) 449

**psychometric validation**  
 of a questionnaire (SELT-M) in patients with advanced cancer 1091

**publication bias**  
 in clinical medicine (Review on evidence-based cancer medicine) 601, 703

**Q**

**quality**  
 of life in patients with  
   breast cancer (Letter to the editor) 231  
   early breast cancer 745  
   Hodgkin's disease 297, S5: 147  
   localized prostate cancer 751  
   lymphoplasmacytoid lymphoma/immunocytoma 499

of life questionnaire for survivors (QLQ-S)  
 in Hodgkin's disease S5: 147

of studies in the field of cancer care (Review) 365

**quantitative PCR**  
 for performing measurements of *bcl-2* mRNA in acute myeloid leukemia 159

**questionnaires**  
 focussing on long-survival cancer patients 549

**R**

**radiation therapy**  
 as a component of high dose salvage strategies in Hodgkin's disease S5: 87  
 in the treatment of malignant mesothelioma (Review) 139

**radiotherapy**  
 added to adjuvant CMF chemotherapy (Commentary) 489  
 in early stage Hodgkin's disease S5: 57, 63  
 of primary extranodal lymphomas of the ocular adnexa (Short report) 779

**Raf-1**  
 related to the treatment of Hodgkin's lymphomas S5: 125

**raloxifene**  
 in combination with tamoxifen as a new treatment for breast cancer (Commentary) 973

**randomized**  
 clinical trials investigating the role of moderate dose escalation in the treatment of advanced stage Hodgkin's disease S5: 73  
 concentration-controlled comparison of standard vs. prolonged infusions of etoposide phosphate in small-cell lung cancer 1205  
 controlled trials in cancer (Review on evidence-based cancer medicine) 483, 827  
 study of recombinant human erythropoietin in solid tumors 255  
 study of the role of pneumatic compression in the treatment of postmastectomy lymphedema 187

**trial of weekly chemotherapy versus cyclical chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma** 633

**trials of carboplatin versus cisplatin in solid tumors (Review)** 13

**Ras**  
 related to the treatment of Hodgkin's lymphomas S5: 125

**recombinant human erythropoietin**  
 in the treatment of chemotherapy-induced anemia 255

**reduced toxicity**  
 in patients with head and neck cancer 505

**Reed-Sternberg cell**  
 in Hodgkin's disease S5: 17

**registry**  
 of incidence, mortality and survival from prostate cancer 31

**relapse**  
 of Hodgkin's disease S5: 91  
 rate  
   after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (Short report) 1023

**remission duration**  
 caused by dose reduction of cladribine in pretreated chronic lymphocytic leukaemia 721

**reporting**  
 randomized trials in cancer (Review on evidence-based cancer medicine) 483

**RER phenotype**  
 of hereditary non-polyposis colorectal cancer 901

**residual mass**  
 after primary therapy for lymphoma (Clinical case) 95

**resistance**  
 of cell lines against cisplatin in patients with ovarian cancer 423

response

- rate as an endpoint for cytotoxic agents in phase II trials of non-small-cell lung cancer 1079
- to novel anti-cancer agents (Special article) 1047

RET mutation

- in patients with medullary thyroid carcinoma (Review) 695

review literature

- on the field of treatment methods of malignant glioma (Review) 589

rhodamine 123

- in primary human breast cancer multiparameter analysis 85

risk factors

- in the addition of etoposide to CHOP chemotherapy in patients with high-grade non-Hodgkin's lymphoma 1213

risk groups

- selecting staging procedures for the treatment of breast cancer patients (Arena) 1173

rituxan

- in the treatment of patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995

RNA-based methods

- in the detection of epithelial tumor cells in blood or bone marrow (Review) 1269

RT-PCR

- performing quantitative measurements of *bcl-2* mRNA 159

**S**

salvage chemotherapy

- for patients with
  - germ cell cancer after failed high-dose therapy (Letter to the editor) 787
  - head and neck cancer (Short report) 225
  - Hodgkin's disease S5: 91
  - Primary refractory Hodgkin's disease S5: 97

salvage radiotherapy

- for patients with primary refractory Hodgkin's disease S5: 97

sarcoidosis

- coincidence of seminoma (Clinical case) 321

scheduling

- in the treatment with paclitaxel of patients with metastatic breast cancer (Short report) 1247

screening

- for prostate cancer and the controversy of complying (Debate) 1283, (Debate) 1293
- for prostate cancer and the risk of overdiagnosis (Debate) 1297
- for prostate cancer with PSA (Editorial) 1263
- to prevent colorectal cancer through sigmoidoscopy 613

secondary analysis

- in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167

secondary malignancies

- after therapy for Hodgkin's disease (Review) S5: 115

second-line doxorubicin

- after high-dose ifosfamide in patients with advanced soft tissue sarcoma (Short report) 783

selective cytoprotection

- with amifostine in concurrent radiotherapy for head and neck cancer 505

seminoma

- and sarcoidosis (Letter to the editor) 924
- coincidence of sarcoidosis (Clinical case) 321

sequelae

- in patients treated with brachytherapy and external beam irradiation for localized prostate cancer 751

serum DNA

- chromosome 3p alterations in (Short report) 113

Sézary syndrome

- prognostic factors and multivariate analysis of clinical, haematological and immunological features 857

SF-36

- health survey in Italian long-survival cancer patients 549

side effects

- of PSA screening for prostate cancer 1293

single agent

- gemcitabine in patients with recurrent ovarian cancer (Short report) 1343

single-cell PCR

- in Hodgkin's disease S5: 17

skin involvement

- in peripheral T-cell lymphoma patients (Short report) 1351

skin lesions

- in Hodgkin's disease (Clinical case) 449

small-cell lung cancer

- bone marrow involvement affecting the prognosis of patients (Review) 247
- improvement and plateau in survival of patients 543
- organ transplantation (Letter to the editor) 339
- positive immunostaining with MluC1 of bone marrow aspirate 181
- treatment with infusions of etoposide phosphate 1205

small lymphocytic lymphoma

- high incidence of relapse after autologous stem-cell transplantation (Short report) 1023

soft tissue sarcomas

- activity in poor prognosis soft tissue sarcomas (Short report) 1131
- activity of doxorubicin after high-dose ifosfamide in adult patients (Short report) 783
- phase II trial of first-line high-dose ifosfamide 871
- treatment with combined high-dose ifosfamide and doxorubicin 877
- treatment with high-dose ifosfamide plus adriamycin (Short report) 917

solid tumours

- the role of erythropoietin in patients (Editorial) 239

somatostatin

- in association with morphine in advanced cancer patients with pain (Letter to the editor) 921

specialization

- on the processes and outcomes of care for cancer patients (Review) 365

staging

- lung neoplasms with the use of FDG-PET 1193
- of breast cancer (Arena) 1173
- of Hodgkin's disease with FDG-PET 1117
- of the tumor grade in patients with ovarian carcinoma 1097

STAT

- factors related to the treatment of Hodgkin's disease S5: 125

statistical models

- for the BEACOPP regimen for advanced stage Hodgkin's disease S5: 73

- stem cell transplant
  - and high-dose therapy for early poor prognosis Hodgkin's disease in first remission S5: 83
- stem cell transplantation
  - from breast cancer patients (Review) 821
- stem cells
  - in breast cancer patients receiving chemotherapy and G-CSF or G-CSF alone (Short report) 913
- supportive care
  - in the treatment of postmastectomy lymphedema 187
- suramin
  - the anti-proliferative effect towards human breast cancer cell lines 205
- surgery
  - of patients with colorectal cancer liver metastasis (Arena) 967
  - of patients with primary cervical malignant teratoma with a rib metastasis (Clinical case) 1015
  - with photodynamic therapy or intracavitary chemotherapy in MM (Review) 139
- survival
  - benefit of low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma 535
  - of patients with
    - adult lymphoblastic lymphoma 619
    - Ewing tumor 275
    - primary extranodal lymphomas of the ocular adnexa (Short report) 779
    - prostate cancer 31
    - small-cell lung cancer 181, 543
    - visceral metastatic melanoma 419
    - vulvar and vaginal cancers 1229
- survivors
  - of Hodgkin's disease S5: 147
- symptom relief
  - with palliative MVP chemotherapy 269
- systematic reviews
  - of published evidence (Review on evidence-based cancer medicine) 703
  - on the treatment of cancer patients (Review) 365
  - using individual patient data (Review on evidence-based cancer medicine) 827
- T**
- T-cell
  - classification of leukemias and lymphomas published by the WHO S5: 25
  - immunity
    - from autologous peripheral stem cell transplantation (Review) SI: 41
- T2-weighted images
  - of the amount of peritumoral edema in the brain 71
- tamoxifen
  - added to adjuvant CMF chemotherapy (Commentary) 489
  - in combination with raloxifene (Commentary) 973
  - in liver disease as potential exacerbation of hepatic dysfunction (Clinical case) 1123
  - used in neoadjuvant chemoendocrine therapy in primary breast cancer 1179
- TARC
- in immune escape mechanisms in Hodgkin's disease S5: 21
- teratoma
  - with a rib metastasis in an adult (Clinical case) 1015
- testicular
  - cancer
    - and the effect of chemotherapy *in situ* 657
    - thoracic metastasectomy 1185
  - teratoma
    - occurrence of Frey's syndrome after cisplatin-based chemotherapy (Letter to the editor) 118
- tetrahydroisoquinolone alkaloids
  - against human tumors explanted from patients 981
- TGF $\gamma$ 
  - in Hodgkin's disease immune escape mechanisms S5: 21
- Th2
  - response of the Reed-Sternberg cells in Hodgkin's disease S5: 21
- therapeutic index
  - of concomitant chemoradiotherapy for head and neck cancer (Editorial) 471
- therapy
  - for Sézary syndrome 857
- thoracic metastasectomies
  - for germ-cell tumours 1185
- thymus hyperplasia
  - as diagnosis for lymphoma 95
- time trends
  - in mortality from prostate cancer 31
  - in incidence, survival and risk of second neoplasms following vaginal and vulvar cancers 1229
- TIPS
  - treatment for patients with a liver disease (Clinical case) 1123
- topoisomerase I
  - in epithelial ovarian cancer 313
  - inhibitors 313
- topotecan
  - in fluoropyrimidine-refractory colorectal cancer 173
- toxicity
  - in conditioning regimens in patients with aggressive non-Hodgkin's lymphoma (Review) SI: 15
  - of drugs in BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67
  - of novel anti-cancer agents (Special article) 1047
  - of paclitaxel (Short report) 569
- training programme
  - for medical oncology (Special article) 585
- transesophageal echocardiography
  - performance in patients with symptoms of systemic arterial embolism (Clinical case) 775
- transferability
  - of economic analysis to make health care decisions (Review on evidence-based cancer medicine) 1167
- transformed follicular lymphoma
  - high-dose therapy with autologous haematopoietic support in patients 865
- transforming growth factor- $\beta$ 
  - in the presence of tamoxifen with human breast cancer 205
- translocation t(11;14)
  - in mantle cell lymphomas 519
- transplantation

in primary refractory Hodgkin's disease S5: 97

of cells in breast cancer patients receiving chemotherapy plus G-CSF or G-CSF alone (Short report) 913

**treatment**

- of advanced non-small-cell lung cancer (Short report) 331
- of chemotherapy-induced anemia 255
- of Hodgkin's disease S5: 133
- of Hodgkin's disease in childhood and adolescence (Review) S5: 115
- of post-transplant lymphoproliferative disease (PTLD) (Letter to the editor) 339
- of stage IIIA (N2) lung cancer (Editorial) 243
- strategy for lymphocyte predominance Hodgkin's disease S5: 39
- with
  - 5-fluorouracil and mitomycin-C (Letter to the editor) 230
  - docetaxel and cisplatin of patients with non-small-cell lung cancer (Short report) 331
  - G-CSF (filgrastim)-supported FEC polychemotherapy 403
  - lamivudine for fulminant reactivated hepatitis B infection (Rapid publication) 385
  - paclitaxel of patients with nasopharyngeal cancer 327
  - paclitaxel in combination with cisplatin in head and neck cancer (Short report) 335
  - palliative MVP chemotherapy 269
  - three cycles of ABVD and high-dose extended irradiation 195
  - vindesine-ifosfamide-platinum induction chemotherapy 261
  - weekly 24-hour 5-FU/leucovorin 45

triazineminopiperidine

- dose limiting toxicities in patients with ventricular arrhythmia and torsade de pointe 1233

tumor growth kinetics

- in patients with advanced stage Hodgkin's disease S5: 73

tumor markers

- in patients with small-cell lung cancer 181
- the role of alpha-fetoprotein (AFP) (Clinical case) 667

tumor vaccine

- strategies in combination with autologous stem cell transplantation (Review) S1: 41

**U**

unknown primary carcinoma

- detection by  $^{111}\text{In}$ -pentetreotide scan 213

**V**

vagina

- descriptive epidemiology of cancers 1229

validation

- of the CFU-GM assay (Special article) 357

veno-occlusive disease

- of the liver induced by gemcitabine (Letter to the editor) 681

vinorelbine

- as a treatment for patients with head and neck cancer (Short report) 225
- in combination with ifosfamide
- in combination with paclitaxel and ifosfamide with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer (Short report) 677
- in patients with anthracycline-resistant metastatic breast cancer (Short report) 565
- in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 1103
- in the treatment of Hodgkin's disease S5: 103

viral pathogenesis

- in Hodgkin's disease S5: 5

vulva

- descriptive epidemiology of cancers 1229

**W**

workshop report

- on Hodgkin's lymphoma and related diseases S5: 31

WT1

- involvement in a Burkitt's lymphoma in a patient with Denys-Drash syndrome 627

**X**

X-ray computed tomography

- after induction chemotherapy in N<sub>2</sub> non-small-cell lung cancer 1193

## Index of authors Volume 9 (1998)

**A**  
Aapro MS 917  
Aaronson NK 739  
Abbruzzese JL 213, 1003  
Abele R 95  
Achterrath W 45  
Ageitos A 1339  
Agelidou M 331  
Ahrens S 275  
Akrivakis C 1139  
Akrivakis K 573  
Albarello L 901  
Albertini P 1351  
Alberto P 95  
Alby N 939  
Alderman E 711  
Alerci M 1262  
Alessandrini F 1173  
Alietti A 779  
Als C 1015  
Alvarez Vincent JJ 1347  
Alvaro T 1355  
Amadori D 255  
Amess JAL 865  
Anchisi S 95  
Anderson JR 717  
Anderson N 13, 573  
Ando Y 845  
Andrade Santiago J 1339  
André T 1251  
Andreoni B 767  
Andrieu J-M 195  
Androulakis N 331, 1127  
Ang PT 327  
Anker G 403  
Ansari RH 1035, 1085  
Antón A 783, 871  
Antón-Torres A 727  
Aparicio J 727  
Apolone G 549  
Apostolidis J 865  
Apostolopoulou F 331  
Appino A 857  
Aranda E 727  
Aravantinos G 1031  
Arends JW 109  
Armand J-P 255, 653, 1103  
Armitage JO 468, 717, 1023, S5: 133  
Arranz F 871  
Asai G 845  
Ascani L 922  
Ascani S 269, 673, 797  
Ashley SE 1179  
Asseryanis E 230  
Asterling S 787  
Astudillo J 113  
Athanassiades A 1031  
Attal M S1: 5  
Attardo G 885  
Au E 327  
Audisio E 55  
Audisio RA 951  
Autier P 581  
Ayers D 1247  
Aylesworth C 733  
**B**  
Baas P 139  
Baccaran M 499  
Bacchi M 535, 877, 1091  
Bafaloukos D 1031  
Bailey NP 633  
Baker SD 101, 173  
Baldini L 779  
Bancher-Todesca D 230  
Bangerter M 1117  
Bardou V-J 619  
Bari A 71  
Barillari G 499  
Barnard DL 633  
Barneto I 727  
Barone C 1199  
Barozzi P 495  
Barrada M 230  
Barry MJ 1279  
Bastian G 1233  
Bastit Ph 1103  
Bauer D 673  
Bauer J 1233, 1315  
Bauknecht T 569  
Bazan C 71  
Beale P 118  
Behringer D 821  
Beijnen JH 437  
Bell D 1343  
Bellmunt J 871  
Belzile M 79  
Benavides M 105  
Bence-Bruckler I 995  
Bendandi M 1351  
Bengtsson N-O 403  
Benner S 1035  
Bennmarker H 403  
Berdel WE 1323  
Bergamaschi D 989  
Berger HM 1331  
Bergh J 403  
Bergmann L 159, 1117  
Berinstein NL 995  
Bernal P 1213  
Bernengo MG 857  
Bernhard J 231, 1091  
Bernhardt W 821  
Bernier J 238, 1268  
Berry G 711  
Bertelli G 187  
Bertelsen K 1301  
Berthillon P 469  
Berthold F 1009  
Bertini M 55  
Bertolini F 913  
Bertoni F 779  
Bertoni G 779  
Bessell EM 633  
Betticher DC 721  
Bianchi M 922  
Bielack SS 893  
Bieling P 893  
Bierling P 453  
Bierman PJ 1023  
Biffi R 767  
Billingham M 711  
Binder M 230  
Bischoff H S5: 67  
Bishop MR 1023  
Bjorkholm E 1301  
Björkholm M 1213  
Blaise D 619  
Blini M 779  
Bodrogi I 639  
Boffi R 922  
Bokemeyer C 787  
Boman K 1301  
Bonardi R 1297  
Bonaventura A 639  
Bonazzi C 1097  
Bonetti A 423  
Boni C 105  
Borchmann P S5: 103  
Borner MM 535, 690, 1315  
Borowski A 519  
Borrás JL 1355  
Bos GMJ 191  
Bosch F 167, 849  
Botta GA 499  
Botto B 55  
Bouabdallah R 619  
Bouafia F 1109  
Boudillet J 1103  
Boylan M 205  
Boyle P 581, 1263  
Bozec L 453  
Braghetti A 796  
Brandariz A 1347  
Bratina G 1097

Bremond A 939  
 Brenner MK S5: 129  
 Bressoud A 877  
 Brière J 195  
 Broggiini M 313  
 Brohée D 921  
 Browman GP 377  
 Bruera E 79  
 Brune D 751  
 Brunet S 849  
 Bryce C 1247  
 Buchmann I 1117  
 Buesa JM 783, 871  
 Bugat R 1343  
 Büntzel J 505  
 Burdach S 275  
 Burks K 173  
 Burnelli R 673  
 Burris H 71  
 Burris III HA 733  
 Bury T 397  
 Buzdar AU 413  
 Buzzi F 639

**C**  
 Cabanillas F 511  
 Cagini L 1185  
 Calvi R 55  
 Calvo R 113  
 Calzas J 457  
 Campbell C 1247  
 Campbell L 1343  
 Campisi C 565  
 Campo E 835  
 Campos D 639  
 Candoni A 499  
 Canellos GP 297, S5: 91  
 Canuti D 1173  
 Capella C 901  
 Capello D 55  
 Cappelaere P 1103  
 Cappello N 857  
 Carbone A 55  
 Carenini N 423  
 Carlisle PS 307  
 Carrato A 727  
 Carreras E 167  
 Cartei G 225  
 Casado A 783, 871  
 Casado V 1339  
 Casassus P 195  
 Casimiro C 1339  
 Cassano R 1140  
 Castagna S 313  
 Castellano D 457, 1347  
 Castiglione M 489, 535, 973, 1091  
 Castrillo JM 849  
 Catalá M 431  
 Cauchie P 921

Cavaletti G 443  
 Cavalli F 7, S5: 109  
 Cavanna L 495  
 Celli DF 297  
 Celsing F 1213  
 Cerna C 885  
 Cerny Th 721, 877, 1015, 1091, 1233  
 Cervantes A 727  
 Cervera E 350  
 Cetto GL 181, 247  
 Chak A 307  
 Chambers S 385  
 Chaney SG 1053  
 Chang J 1179  
 Chapman ALN S5: 5  
 Chapman BA 385  
 Chasen MR 217  
 Chaudri HA 639  
 Chauvergne J 1103  
 Cherin E 297  
 Chiari S 1097  
 Child JA 633  
 Christensen TB 657  
 Ciatto S 1297  
 Cid J 849  
 Cifani S 549  
 Cisneros A 1123  
 Clark FL 385  
 Clark G 981  
 Clarke M 827  
 Clavero-Fabri M-C 653  
 Cleton FJ 1331  
 Coates AS 419, 489, 973  
 Cocorocchio E 913  
 Cocquyt V 1243  
 Codegoni AM 313  
 Coebergh J-WW 543  
 Cognetti F 1199  
 Cognetti F 565  
 Coiffier B 803, 1109, S1: 5  
 Colleoni M 489, 951, 1140  
 Colli E 989  
 Colombi M 779  
 Colombo N 977  
 Colomer D 167  
 Colonna P 195  
 Conter V 673  
 Conti PS 924  
 Cook GJR 353  
 Cooper GS 307  
 Cooper MR 297  
 Cornaggia M 901  
 Corrado C 151  
 Cortés-Funes H 105, 457, 1347  
 Cosset J-M S5: 57  
 Costa A 228  
 Cote C 1199  
 Couette J-E 751  
 Coyle D 475

Craft A 275  
 Crombet T 431  
 Crommelin MA 543  
 Cullen MH 633  
 Curé H 37  
 Cvitkovic E 453, 1053  
 Czuczman M 995

**D**  
 Da Prada GA 913  
 Dąbrowska A 63  
 Daenen M 1355  
 Dalesio O 437  
 Dallavalle G 105  
 Daugaard G 657  
 Dauplat J 939  
 Davidson K 885  
 De Braud F 105, 767, 917  
 De Conno F 79, 922  
 De Gramont A 1251  
 De Haes JCJM 745  
 De Jong J 1315  
 De Koning HJ 1293  
 De Leyn PR 261, 1193  
 De Matteis A 857  
 De Mulder PHM 321, 924  
 De Pas T 917  
 De Sanctis V 1027  
 De Tribollet N 580, 589  
 De Wolf F 1135  
 Debat P 453  
 Deconinck E S1: 5  
 Deeks JJ 375, 703  
 Degardin M 1103  
 Del Favero A 811  
 Del Mastro L 187, 461  
 Delling G 893  
 Delmer A 129  
 Delsol G 835, S5: 31  
 Delval L 921  
 Demedts MG 261, 1355  
 Deneffe GJ 261  
 Desablens B 195  
 Desmery P 151  
 DeWolf-Peeters C S5: 31  
 D'Incalci M 313, 937, 1315  
 Di Loreto C 499  
 Diaz-Canton EA 413  
 Diaz-Rubio E 105, 727  
 Diebold J 835, S5: 25  
 Diehl LF 297  
 Diehl V 221, 283, 289, S5: 1, 39, 67, 73, 79, 103,  
     147  
 Diéras V 37  
 Diergarten K 335  
 Dietrich PY 589  
 Dignani C 151  
 Dimopoulos A-M 331, 1031  
 Dimopoulou I 1127

Dini D 187  
 Dirix L 1199  
 Dobbie M 681  
 Dockhorn-Dworniczak B 275  
 Domine M 1339  
 Donato V 1027  
 Donehower RC 101, 173  
 Dong K 511  
 Donovan JL 1289  
 Doveil GC 857  
 Doyen Ch SI: 5  
 Drengler R 71  
 Drinkard LC 647  
 Drudi G 1173  
 Drummond MW 385  
 Ducreux M 653  
 Dühmke E S5: 67  
 Dulude H 1247  
 Dumontet C 1109  
 Dunn J 633  
 Dunst J 275  
 Dupont PJ 1193

**E**  
 Earle CC 475  
 Eberhardt W 45  
 Eckardt JR 71, 733  
 Eckhardt SG 733, 981  
 Eghbali H S5: 147  
 Eisenhauer EA 1047  
 Eisinger F 939  
 Elewaut AE 1243  
 Elisaf MS 449  
 Elsner K 1117  
 Engert A 289, S5: 1, 67, 79, 103  
 Enkin MW 963  
 Epler D 893  
 Erba E 989  
 Erikstein B 403  
 Erler G 31  
 Errante D 923  
 Escudero P 783, 871  
 Espié M 939  
 Esteve J 167  
 Estevez L 1339  
 Evans WK 475  
 Evers LM 1135

**F**  
 Fabbrica D 443  
 Fabi A 565  
 Faircloth G 981, 989  
 Falasca E 499  
 Falini B 797  
 Fandi A 653  
 Fandi L 653  
 Fanin R 499  
 Fargeot P 1103  
 Farish J 633

Fassone F 653  
 Fattori PP 1173  
 Fazio N 917  
 Feingold J 939  
 Feleszko W 63  
 Feller AC 835  
 Felman P 1109  
 Ferguson MK 647  
 Fermé C S5: 147  
 Fernandez de Sevilla A 849  
 Fernández I 151  
 Ferrari A 627  
 Ferrari MG 495  
 Fetscher S 821  
 Fey MF 535, 568, 721  
 Fiebig HH 1323  
 Fiebiger W 1309  
 Fields-Jones S 71  
 Fierro MT 857  
 Filez L 1199  
 Filiberti A 549  
 Filshie J 118  
 Finizio M 101  
 Finkle C 885  
 Fisher RI S5: 121  
 Fishkin PAS 1085  
 Flath B 573, 1139  
 Flechtner H S5: 147  
 Fletcher J 633  
 Floren LC 1123  
 Foran JM 865  
 Ford HT 1179  
 Fornander T 403  
 Forno G 187  
 Forral K 733  
 Fossati-Bellani F 627  
 Fossati V 779  
 Fountzilas G 1031  
 Fra J 783  
 Franceschi S 31  
 François S 195  
 Franklin J S5: 39, 67  
 Fraternali-Orcioni G 607, 1351  
 Frattola L 443  
 Freilone R 55  
 Frickhofen N 1117  
 Friederich P 639  
 Friedlander M 1343  
 Fröhlich B 275  
 Fröhlich D 505  
 Fromont P 453  
 Frye D 413  
 Fuchs N 893  
 Fumoleau P 1103  
 Furlan D 901

**G**  
 Gaidano G 55  
 Gambirasio F 627

Gamucci T 255  
 Garcia AA 1131  
 Garcia-Carbonero R 1347  
 Garcia JC 1035  
 Garcia-Conde J 727, 849  
 García del Muro J 783, 871  
 Garrone O 187  
 Garufi C 1199  
 Gascoyne RD S5: 31  
 Gastaut J-A 619  
 Gaulard Ph 835, SI: 5  
 Geertsen PF 657  
 Geffen DB 1142  
 Gelber RD 489, 973  
 Gelmon KA 1045, 1247  
 Genvresse I 573  
 Geoffrois L 1103  
 Georgii A S5: 31, 67  
 Georgopoulou T 1127  
 Georgoulas V 331, 1127  
 Geraghty JG 951  
 Gerard B 1233  
 Geroyianni A 1127  
 Gershonovich M 639  
 Ghandour C 195  
 Gharib H 695  
 Gherlinzoni F 1351  
 Ghielmini M 8, 357, 989  
 Giardini R 627  
 Gibelli N 913  
 Giermasz A 63  
 Giroux B 1233  
 Gisselbrecht C 835, SI: 5, SI: 15  
 Giuffrida D 695  
 Glaser C 559  
 Glatzel M 505  
 Glunz A S5: 67  
 Godwin J 827  
 Goedhals L 661  
 Golab J 63  
 Goldblum R 71  
 Goldhirsch A 489, 535, 767, 810, 917, 973, 1140  
 Goldman JM 351  
 Goldstone AH SI: 9, S5: 83  
 Goldstraw P 1185  
 Golomb HM 677, 1085  
 Gomez L 885  
 Gómez H 457  
 Gómez-Martin C 457  
 Gonzalez M 849  
 González G 431  
 González Y 431  
 Gordon M 357  
 Gozza A 187  
 Graf N 893  
 Gralla RJ 811  
 Gravel D 1003  
 Gray JE 101  
 Green D 995

Green M 691  
 Greenberg D 297  
 Greiner TC 339  
 Gridelli B 673  
 Grieshaber CK 357  
 Grieshammer M 1117  
 Grieve RJ 633  
 Grilli R 365  
 Grillo-López AJ 995  
 Grimfors G 1213  
 Grochow LB 101, 173  
 Groff L 79  
 Gross TG 339  
 Grote W 519  
 Gruia G 1199  
 Grunicke HH S5: 125  
 Guastalla JP 37  
 Gucalp R 307  
 Gueli-Alletti D 977  
 Guerra JA 457  
 Guetty-Alberto M 95  
 Guffanti A 779  
 Guidi G 181  
 Guilhot F 195  
 Guillén G 431  
 Gumà J 1355

**H**  
 Hadovsky G 71  
 Haedicke C S5: 67  
 Hafner M 1117  
 Hagemeister FB 511  
 Hagenbeek A 191  
 Haioun C S1: 5  
 Hammond L 71  
 Hanauske A-R 335  
 Hander T 71  
 Hanselmann S 535  
 Hansen HH 585  
 Hansmann M-L S5: 17, 39  
 Hanson J 79  
 Haraf DJ 647  
 Harder S 519  
 Hárting B 569  
 Harnett P 1343  
 Harousseau J-L 195  
 Harris NL 835, S5: 25, 31, 45  
 Harstrick A 45  
 Hasenclever D S5: 67, 73  
 Hatzidakis D 331, 1127  
 Hauns B 569  
 Häusler R 1015  
 Håvard Loge J S5: 137  
 Havik E 437  
 Haward RA 1073  
 Haynes RB 377  
 Hebert MF 1123  
 Hedlund A 1213  
 Hegewisch-Becker S 85

Heimans JJ 739  
 Heinrich B 335  
 Heise U 893  
 Hejna M 1309  
 Helwig S 1091  
 Henderson E 297  
 Henry-Amar M 751, S5: 147  
 Henschler R 821  
 Heras P 331  
 Hermann R S5: 67  
 Hermans J 1219  
 Hernández JC 431  
 Herndon II JE 297  
 Héron J-F 661, 751  
 Herrmann R 229, 255, 535, 681, 877, 967  
 Herzog M 335  
 Heslop H S5: 129  
 Hess U 721  
 Heusser P 1091  
 Hickish T 269, 1179  
 Hidalgo M 457, 1347  
 Higgins A 1205  
 Hillen HFP 109  
 Himmelmann A 1301  
 Hinrichs SH 339  
 Hitt R 1347  
 Hoelzer D 159  
 Hofer S 681  
 Hoffman PhC 647, 677, 1085  
 Hogberg Th 1301  
 Holland JC 297  
 Holmer L S5: 67  
 Homerin M 105  
 Hopman GD 1331  
 Hoppe RT S5: 87  
 Hornbuckle K 307  
 Horning SJ S5: 97  
 Hortobagyi GN 413, 1151  
 Horvath G 1301  
 Horwitz A 1185  
 Hösli P 589  
 Hossfeld DK 85, 585  
 Hsu Schmitz S-F 721  
 Hubens G 907  
 Humblet Y 1199  
 Humerickhouse R 1035  
 Hunt DL 377  
 Hupperets PSGJ 109  
 Hürny C 1091  
 Hustinx R 397

**I**  
 Igarashi T 527  
 Iggo R 462  
 Infantil L 499  
 Inselmann G 775  
 Ionta MT 565  
 Iop A 225  
 Isaia A 225

Iwan-Osiecka A 63  
 Izbicka E 885, 981

**J**  
 Jack A 633  
 Jacobsen A 1301  
 Jacquet N 397  
 Jacquin JP 37  
 Jadad AR 963  
 Jaffe ES 835, S5: 25, 31  
 Jahns R 775  
 Jais J-P 195  
 Jakóbisiak M 63  
 Janiaud P 939  
 Jansen RHL 109  
 Janssen-Heijnen MLG 543  
 Jeffrey M 639  
 Jensen Hjermstad M S5: 137  
 Jerusalem G 397  
 Jimeno J 981, 989  
 Joel S 1205  
 Joly F 751  
 Joos S 519  
 Joosten-Achjanie SR 109  
 Jordan VC 1123  
 Joss RA 667  
 Jost LM 51  
 Josting A 289, S5: 147  
 Jox A 283  
 Judson I 118  
 Jungi F 682  
 Juni M 151  
 Jürgens H 275, 893

**K**  
 Kaasa S S5: 137  
 Kaca A 63  
 Kadin ME S5: 31  
 Kaern J 1301  
 Kagami Y 527  
 Kakolyris S 331, 1127  
 Kalogera-Fountzila A 1031  
 Kamataki T 845  
 Kanzler H 283  
 Karakas T 159  
 Kátay I 289  
 Kau R 335  
 Kaufman SS 339  
 Kayitalire L 1343  
 Keating MJ 131  
 Kellokumpu-Lehtinen P 403  
 Kemmerich M 335  
 Kempf RA 1131  
 Kenn W 775  
 Keramopoulos A 1031  
 Kersten MJ 1135  
 Kessinger A 1023, S1: 23  
 Ketterer N 1109  
 Khouri IF 131

Kim EE 213  
 Kinoshita T 527  
 Kinser JA 1015  
 Klaassen U 45  
 Kleisbauer J-P 661  
 Klepsch A 1085  
 Klinkhamer PJM 543  
 Kluin-Nelemans JC 1219  
 Kluin PM 1219  
 Knobel H S5: 137  
 Knöppel-Schwarz S 221  
 Kobayashi Y 527  
 Köhne C-H 967  
 Kollath JP 1023  
 Körholz D 893  
 Kornacker M 283  
 Kornblith AB 297  
 Kornek GV 1309  
 Kosmidis P 1031  
 Kotsakis A 1127  
 Kotz R 893  
 Kotzerke J 1117  
 Kourousis C 331  
 Kouroussis C 1127  
 Krause S S5: 67  
 Krauseneck P 232  
 Krauss SA 677, 1085  
 Kraynak MA 71, 733  
 Kröger N 85  
 Kubista E 230  
 Kubota K 1079  
 Kugler JW 1035  
 Kumagai K 117  
 Kuoppola T 1301  
 Küppers R 283, S5: 17  
 Kurowski Ch 1009  
 Kurrer MO 51  
 Kutteh LA 307  
 Kuttenn F 939  
 Küttnner K 505  
 Kwak LW S1: 41

**L**  
 La Targia ML 779  
 La Vecchia C 31, 1229  
 Labianca R 105, 365  
 Lad TE 1085  
 Laeng H 1015  
 Laffer UTh 1150  
 Lage A 431  
 Lambert HE 229  
 Lambrechts AC 1269  
 Lancaster J 71  
 Langnas AN 339  
 Lanza A 913  
 Lasek W 63  
 Lassus M 639  
 Lathan B 221, S5: 67  
 Laubenbacher C 335

Lawrence R 885, 981  
 Lazarus HM 307  
 Le Prisé P-Y 195  
 Lebrun J-P 939  
 Leduc B 37  
 Lefranc J-P 939  
 Leitha T 559  
 Lejeune F 195, 694  
 Lemevel A 195  
 Lenaz L 45  
 Lentjes EGWM 1331  
 Lentz MA 1103  
 Lenzi R 213  
 Leone R 423  
 Lepage E S1: 5  
 Lerut TE 261  
 Lesaunier F 751  
 Levi F 31, 1229  
 Lévi F 453  
 Leyvraz S 535, 877, 1233  
 Lianes P 457  
 Liberati A 365  
 Lievens YN 261  
 Liliemark J 1213  
 Lionetto R 187  
 Lisa F 857  
 Lissoni A 877, 977  
 List M 1035  
 Lister TA 865  
 Lobo F 1339  
 Loeffler M S5: 67, 73  
 Lokich J 13, 573  
 Long JEH 217  
 Longo G 495  
 Löning T 85  
 Lopez A 849  
 Lopez-Guillermo A 167, 849  
 López-Cabrerizo MP 113  
 López-Pousa A 783, 871  
 López-Vega JM 727  
 Lorenz M 967  
 Louvet C 1251  
 Lowe S 228  
 Lubiniecki GM 101  
 Lucianetti A 673  
 Ludwig H 639  
 Lüftner D 1139  
 Lum B 711  
 Lund B 1301  
 Luppi M 495  
 Lurie H 639  
 Lynch M 205

**M**  
 Maartense E 1219  
 Machaj E 63  
 MacLennan KA S5: 31  
 Magagnoli M 1351  
 Magnani I 423

Maier-Lenz H 569  
 Makris A 1179  
 Malmström P 403  
 Maloney D 995  
 Mandelli F 1027  
 Mangioni C 313, 977, 1097  
 Mani S 1035  
 Maraninchi D 619  
 Marasca R 495  
 Maraveyas A 239  
 Marinello P 431  
 Mariuzzi L 499  
 Marosi C 559  
 Marsolais C 885  
 Martelli M 1027  
 Martelli MP 1027  
 Martin FJ 711  
 Martin J 783  
 Martin J 871  
 Martinelli G 913  
 Martinez Rolón J 151  
 Martini N 243  
 Mascia T 495  
 Masi A 1173  
 Masip C 1355  
 Masotti A 181  
 Massidda B 565  
 Massimino M 627  
 Massutti T 727  
 Masters GA 677, 1085  
 Matthews J 865  
 Matthiesen P 519  
 Mattmann S 667  
 Mauch PM S5: 57  
 Mauer AM 677  
 Maurer R 51  
 Maurer U 159  
 Mauri S 767  
 Mavromanolakis E 331  
 May D 580  
 Mayer RJ 297  
 Mazza U 55  
 Mazzotta A 1297  
 McLaughlin P 511, 995  
 Meerpohl HG 569  
 Mellink WAM S5: 147  
 Menendez D 871  
 Mergenthaler HG 1139  
 Merk K 1213  
 Mertelsmann R 821  
 Messori A 389  
 Metzke S 519  
 Michelassi F 1035  
 Michelet M 151  
 Middleton GW 269  
 Miethling CC 159  
 Mignot L 37  
 Miholic J 1309  
 Milani M 607, 673

Milionis HJ 449  
 Millán JM 1347  
 Millward MJ 1343  
 Milone G 151  
 Minolia C 443, 1315  
 Minozzi S 365  
 Mirabal V 431  
 Missel JT 453  
 Moher D 483  
 Mondini P 627  
 Monfardini S 255  
 Montalban C 849  
 Montserrat E 167, 835, 849  
 Monzó M 113  
 Moog F 1117  
 Molenaar WH 437  
 Moon T 511  
 Morant R 535  
 Morel P SI: 5  
 Moreno JA 1343  
 Morishima Y 527  
 Morselli M 495  
 Mosconi P 549  
 Mouillet I 1109  
 Moulopoulos LA 1250  
 Mounier N SI: 15  
 Mousseau M 37  
 Mross K 569, 1323  
 Muggia FM 924, 1131  
 Müller MJ 739  
 Müller-Hermelink HK S5: 25, 31  
 Munzone E 917  
 Murate T 527

**N**  
 Nackaerts KL 261, 1355  
 Nagler A SI: 31  
 Nakashima L 1247  
 Narabayashi M 527  
 Nash AG 1179  
 Nasti G 923  
 Neal DE 1289  
 Neidhart-Berard E-M 1109  
 Neri A 779  
 Neri B 255  
 Netter-Pinon J 255  
 Neuenschwander H 120, 474  
 Neumann K 45  
 Neymark N 1167  
 Ng CYC S5: 129  
 Nicholson AG 1185  
 Nicol SJ 733  
 Nicolaides C 1031  
 Nishiwaki Y 1079  
 Nolé F 767, 917, 1140  
 Noordijk EM 1219, S5: 63  
 Norfolk D 633  
 Norton A 269  
 Norton AJ 865

Norum J 613  
 Novelli M 857  
 Novero D 55  
 Nowrouzian MR 255

**O**  
 O'Brien MER 269  
 O'Byrne K 1205  
 O'Higgins N 639  
 O'Reilly S 101, 173, 1247  
 Oberhoff C 255  
 Oberholzer M 681  
 Obermair A 230  
 Obrist R 1043  
 Ogura M 527  
 Ohtsu T 527  
 Oliveira J 1103  
 Oliver RTD 787  
 Olszewski 745  
 Onsrud M 1301  
 Orfeuvre H 37  
 Orlando L 917, 1140  
 Orsi F 767  
 Orsucci L 55  
 Orvieto E 1140  
 Osanto S 1331  
 Ösby E 1213  
 Ossenkoppele GJ 739

**P**  
 Pagani O 535, 661, 1233, 1315  
 Pajak TF 471  
 Palestro G 55  
 Palombi F 1027  
 Pampallona S 989  
 Panzini I 1173  
 Paolicchi A 423  
 Papadakis E 331, 1127  
 Papadimitriou C 331, 1031, 1127  
 Papaldo P 565  
 Papamichael D 865, 1205  
 Papi M 1173  
 Parchment RE 357  
 Pariso D 37  
 Parker P 307  
 Parsa-Parsi R S5: 1, 79  
 Parvis G 55  
 Pasini F 181, 247  
 Pasini G 1173  
 Pasquini E 1173  
 Pastore C 55  
 Pastorino U 1185  
 Patek A 711  
 Patriarca F 499  
 Patton WN 385  
 Pau FM 1027  
 Paulus P 397  
 Paulus U S5: 67  
 Paulussen M 275

Pauwels P 321  
 Pavanel F 181  
 Pavletic ZS 932, 1023  
 Pavlidis N 1031  
 Pavlovsky S 151  
 Paz-Ares L 457  
 Peccatori F 913  
 Pellegrino A 977  
 Pelosi G 181, 247  
 Peña M 1347  
 Penson R 1205  
 Pény J 751  
 Perego P 423  
 Pereira J 79  
 Pernet FPPM 321  
 Perotti C 913  
 Perotti D 627  
 Perry AR SI: 9  
 Peruzzotti G 1140  
 Pescarmona E 1027  
 Pestalozzi B 535  
 Peterson BA 297  
 Petrides PE 1139  
 Petry KU 255  
 Pettengell R 239  
 Pfreundschuh M S5: 67  
 Philippou Pari C 45  
 Piccart MJ 133, 461  
 Pichert G 51  
 Pichlmeier U 85  
 Pieniaszek Jr HJ 101  
 Pierotti MA 627  
 Pierret J 939  
 Pierson JL 1023  
 Pifarré A 113  
 Pileri SA 607, 673, 797, 1351  
 Pipan C 499  
 Plate KH 1155  
 Plendl H 519  
 Plunkett W 1003  
 Poggi S 673  
 Pojda Z 63  
 Polselli A 1173  
 Pont J 787  
 Poppema S S5: 21, 31  
 Posner MC 1035  
 Possinger K 573, 1139  
 Postma FR 437  
 Postma TJ 739  
 Potters M S5: 21  
 Poveda A 783, 871  
 Powles TJ 1179  
 Pozzi S 767  
 Pozzo C 1199  
 Priest K 269  
 Prinz B 1139  
 Pruckmayer M 559  
 Puglisi F 499  
 Puistola U 1301

Pujade-Lauraine E 37

**Q**  
 Quaglino P 857  
 Quasthoff S 335

**R**  
 Raber MN 213, 1003  
 Raderer M 1309  
 Radice P 627  
 Ragaz J 1247  
 Rahman Z 413  
 Rajewsky K S5: 17  
 Ramaccioni V 673  
 Randimbison L 31, 1229  
 Ratain MJ 1085  
 Ratschiller D 721  
 Ravaioli A 1173  
 Raymond E 981, 1053, 1251  
 Rebmann U 255  
 Reichardt P 639  
 Reiss P 1135  
 Renard J 1315  
 Rendina EA 1027  
 Resegotti L 55  
 Reske SN 1117  
 Reyes F S1: 5  
 Reymann A 85  
 Ribera JM 849  
 Richardson P 711  
 Rickinson AB S5: 5  
 Rielly S 1247  
 Rigo P 397  
 Rinaldi DA 733  
 Rio B 129  
 Ripamonti C 79, 922  
 Ripoche V 1343  
 Robertshaw H 1205  
 Robertson C 1140  
 Robles L 1339  
 Robustelli della Cuna G 913  
 Rodenhuis S 437, 1269  
 Rodriguez-Diaz Pavón J 511  
 Rodriguez GI 733  
 Rodriguez MA 511  
 Rodriguez-Monge E 413  
 Rogato A 499  
 Rogers M 1131  
 Roggero E 519  
 Rohatiner AZS 865  
 Roila F 811  
 Rolland F 1103  
 Romaguera JE 511  
 Romanelli S 423  
 Romieu G 639  
 Ronchi A 1315  
 Rooney CM S5: 129  
 Rosell R 113  
 Rosenberg J 995

Roskrow MA S5: 129  
 Rösler H 1015  
 Ross P 229  
 Rota S 1097  
 Rothenberg ML 71, 733  
 Rougier P 653  
 Rovira M. 167  
 Rowinsky EK 101, 173, 885  
 Rubiò J 1355  
 Rudd R 1205  
 Rüdiger T S5: 31  
 Rueffer U 289  
 Ruff P 217  
 Rüffer J-U S5: 67, 147  
 Ruggiata R 549  
 Rustin GJS 229

**S**  
 Sabattini E 607, 797  
 Sacco C 55  
 Saglio G 55  
 Saito N 1079  
 Sainty D 619  
 Saka H 845  
 Sakai C 117  
 Salar A 849  
 Salata RA 307  
 Salles G 803, 1109  
 Salmaso F 499  
 Salmi T 1301  
 Salzer-Kuntschik M 893  
 Sammut PH 339  
 Samuels BL 677  
 Sánchez-Céspedes M 113  
 Sandvei R 1301  
 Sappino AP 589  
 Sarkany M 1233  
 Sartorius S 101  
 Sasaki M 1155  
 Sasaki Y 527, 1079  
 Sastre J 105, 727  
 Schaad R 1091  
 Schefer H 667  
 Scheistroen M 1301  
 Scheithauer W 1309  
 Schellong G S5: 115  
 Schiffer C 297  
 Schilling A 297  
 Schilsky RL 1035  
 Schipper RM 543  
 Schläpfer J 1233  
 Schlegelberger B 519, 835  
 Schmitter D 51  
 Schnell R S5: 103  
 Schouten HC 109  
 Schouwink H 139  
 Schrijvers D 907  
 Schröder FH 1293  
 Schulz KF 483

Schweigert M 1139  
 Schwonzen M 221  
 Sciortino DF 1035, 1085  
 Scovassi AI 313  
 Seeber S 45  
 Seitz R 1255  
 Sekine I 1079  
 Serreyn R 1243  
 Sessa C 357, 661, 877, 977, 989, 1233, 1315  
 Sextro M S5: 67  
 Shamash J 787  
 Sharma A 733  
 Sheldon TA 365  
 Shen D 995  
 Shenkier T 1247  
 Shimokata K 845  
 Shipp MA S1: 47  
 Shulman KL 1035  
 Sieber M S5: 67, 147  
 Siebert R 519  
 Sierra J 167  
 Silver RT 297  
 Silvestri F 499  
 Simmons AV 633  
 Simonsen E 1301  
 Siu LL 885  
 Skarlos D 1031  
 Slavin S S1: 31  
 Slevin M 1205  
 Smith IE 269  
 Smith T 413  
 Snijder S 1219  
 Sobol H 939  
 Somberg KA 1123  
 Somville J 907  
 Sorbe B 1301  
 Souglakos J 1127  
 Sparano J 307  
 Spataro V 23, 936  
 Späth-Schwalbe E 573  
 Spencer L 269  
 Spina M 923  
 Spyridonidis A 821  
 Stack C 633  
 Stahel RA 51  
 Staib F 85  
 Staib P 221  
 Stappert-Jahn U S5: 67  
 Starkhammar H 1199  
 Stein H S5: 31  
 Steinmetz HT 221  
 Stephens CD 733  
 Sternberg C 1044  
 Steward WP 1265  
 Stoklosa T 63  
 Stolte M 775  
 Stoppa A-M 619  
 Stoppa-Lyonnet D 939  
 Stroobants SG 1193

Strumberg D 45  
 Stuart NSA 633  
 Stupp R 1233  
 Sugiyama S 845  
 Suzuki N S5: 129  
 Svedmyr E 1213  
 Svetec D 1283

**T**  
 Taamra A 1053  
 Tabernero JM 727  
 Taborelli M 901  
 Takagi T 117  
 Talbot D 1205  
 Tamura T 1079  
 Tan EH 327  
 Tassinari D 1173  
 Tavio M 923  
 Te V-C 31  
 Terzoli E 1199  
 Tesch H 221, 289, S5: 39, 67, 79  
 Theiss F 335  
 Thieblemont C 1109  
 Thigpen JT 933  
 Thödtmann R 335  
 Tholander B 1301  
 Thomas A 1265  
 Thompson IM 1283  
 Thouvenin D 939  
 Tibelli MG 901  
 Tichelli A 721  
 Tidy VA 1179  
 Tilly H S1: 5  
 Timothy AR 353  
 Tinazzi A 365  
 Tirelli U 923  
 Tjan-Heijnen VCG 321, 924  
 Tobinai K 527  
 Tobler A 721  
 Todisco E 1027  
 Tolcher A 1247  
 Tomao S 565  
 Tonato M 811  
 Torelli G 495  
 Torretta L 913  
 Torri V 1097  
 Torti F 711  
 Tournigand C 1251  
 Tourotoglou N 1003  
 Tredici G 443  
 Trépo C 469  
 Très A 727  
 Tresca P 1103  
 Tristant H 939  
 Tropé C 1301  
 Tschümperlin B 673  
 Tubiana-Mathieu N 37, 255  
 Tummarello D 181  
 Tura S 1351

Tzannes S 331, 1127  
**U**  
 Unger C 569, 1323  
 Urbano-Ispizua A 167

**V**  
 Vaccher E 923  
 Valencak J 1309  
 Valenti C 495  
 Valenti V 871  
 Valero V 413, 1151  
 Vallisa D 495  
 Van Belle S 1243  
 Van Bleyenbergh P 1355  
 Van Cutsem E 1199  
 Van Deijk WA 1219  
 Van den Bent M 191  
 Van den Berg AM S5: 21  
 Van den Berg HW 205  
 Van der Burg MEL 229  
 Van der Holt B 191  
 Van der Schueren E 261  
 Van Glabbeke M 1103  
 Van Oers MHJ 1135  
 Van Oosterom A 907  
 Van Putten WLJ 191  
 Van Raemdonck DE 261  
 Van Rensburg CEJ 217  
 Van Schil P 907  
 Van 't Veer LJ 1269  
 Van Trappen Ph 1243  
 Van Wegberg B 1091  
 Vandelli L 495  
 Vandervelde A 1355  
 Vansteenkiste JF 261, 1193, 1355  
 Vardakas N 1127  
 Varette C 1343  
 Vartianen J 1301  
 Velagapudi R 1323  
 Venook AP 1123  
 Venturini M 187, 461  
 Verbeken EK 1193  
 Verdonck LF 191  
 Verduyn TJ 1135  
 Verlato G 181  
 Vermorken JB 585, 739  
 Verweij J 807  
 Viale G 1140  
 Vicente J 1339  
 Vidili G 187  
 Viens P 37  
 Vijuk G 419  
 Villalona-Calero MA 71, 733  
 Villamor N 167  
 Villing A-L 653  
 Vincent P 37  
 Visser L S5: 21  
 Vitolo U 55

Vitvitski L 469  
 Vlachonikolis J 331  
 Vlasveld LTh 321, 924  
 Voigtmann R 255  
 Vokes EE 471, 647, 677, 1035, 1085  
 Voliotis D 221  
 Volovics A 109  
 Volpe D 357  
 Volpe G 55  
 Von Broen IM 1323  
 Von der Maase H 657  
 Von Hoff DD 71, 733, 885, 981,  
 Von Kalle K S5: 67  
 Von Rohr A 721  
 Von Rohr E 1091  
 Vose JM 1023, S1: 1  
 Vossos A 331

**W**  
 Wagener DJTh 585  
 Watine J 1255  
 Watson S 677  
 Weber B 37  
 Weber BL 929  
 Weber-Matthiesen K 519  
 Weber W 535  
 Weidmann E 159  
 Weijl NI 1331  
 Weil C 1315  
 Weinel P 893  
 Weinländer G 1309  
 Weisenburger DD 717, 1023  
 Weiss GR 733  
 Weiss LE S5: 31  
 Weiss RB 297  
 Wernecke KD 1139  
 Werner M 893  
 Wernli M 721  
 Westberg R 1301  
 Westermann AM 437  
 Westra A 907  
 Weyler J 9  
 White CA 995  
 Wickramanayake PD 221, 289  
 Widell S 1213  
 Widmer L 51  
 Wijermans PW 1219  
 Wiklund T 403  
 Wilke H 45  
 Wilking N 403  
 Williams CJH 375, 601  
 Winkelmann W 275  
 Winkler K 893  
 Winner J 339  
 Winnerlein-Trumpf E S5: 67  
 Winter S 289  
 Wipkink-Bakker A 1331  
 Wittes RE 251  
 Wobst A 951

Wolchok S 297  
Wolf J 283, S5: 67, 79  
Woodroffe CM 633  
Wu CD 1023  
Wulf G S5: 67  
Wyka D 677

**Z**  
Zagożdżon R 63  
Zagonel V 55  
Zaja F 499  
Zampino MG 917  
Zander T 283  
Zanetta G 977, 1097  
Zaniboni A 105  
Zappa M 1297  
Zappala A 565  
Zarba J 653  
Zhang Y 519

Zibera C 913  
Zinzani PL 1351  
Zittoun R 129  
Zoetmulder FAN 139  
Zoubek A 275  
Zucca E 519, 835  
Zucchetti M 1315  
Zuckerman E 297  
Zühlke-Jenisch R 519  
Zulian G 721  
Zunino F 423  
Zwierzina H 255

**X**  
Xerri L 619

**Y**  
Yoder O 251